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The p63 gene encodes multiple protein isoforms that function as sequence specific transcription factors, which can regulate both p53 dependent and independant target genes. Of these, ΔNp63α has been identified as one of the most important isoforms. It is the principal isoform that acts as a crucial regulator of embryonic development. It is also the predominant isoform that is upregulated in some human cancers, thus supporting an important role in human neoplasia.  

p63 protein is widely reported to be overexpressed in more than 80% of  primary head and neck squamous cell carcinomas (HNSCC), and this high expression has been reported to have prognostic implications in these patients. It has also been reported that ∆Np63 is expressed in pancreatic cancers. However, expression of ∆Np63 in pancreatic cancers varies from 8% to 68.2%, and it has not yet been related to any clinicopathological features. In addition, little is known about how ∆Np63 affects prognosis and tumour cell biology in pancreatic cancers. In an effort to further understand the role of ΔNp63α in HNSCC and elucidate the contribution of ΔNp63α in human pancreatic ductal adenocarcinoma, this study has sought to identify the functional effects of ΔNp63α on tumour biology and ultimately novel transcriptional targets for ΔNp63α through the use of gene expression profiling. 

Using immunohistochemistry analysis of primary human HNSCC and PDAC tissue samples, this has confirmed ΔNp63α is overexpressed in a spectrum of neoplasias in both tumour models. Its expression pattern is suggestive of a role in cell differentiation and overall, it correlates with significantly poorer prognosis for primary pancreatic cancers. 

RNA interference with four independent p63 targeting sequences have been used to downregulate ΔNp63α expression in the p63 positive carcinoma cell lines from the two selected tumour models. Using this approach, several important biological functions have been determined. The cellular effects of ΔNp63α expression on tumourigenicity, cancer cell migration, invasion and its effect on chemosensitivity have been determined. The results have identified an important role for ΔNp63α in cancer initiation and also its part in contributing to tumour progression. 
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Worldwide, 10.9 million people are diagnosed as suffering from cancer each year [1]. In the United Kingdom 276,678 people were diagnosed with cancer in 2003, and 153,397 people died from this disease in 2004 [2]. World population growth and ageing would imply a progressive increase in the cancer burden. It is expected that there will be 15 million new cases and 10 million new deaths from cancer in 2020, even if current rates remain unchanged [3]. This has led to cancer research being the biggest area of medical research [4].

1.1.2 Cancer Biology























Fig 1.1: Acquired capabilities of cancer [5].

Self sufficiency in growth signals is one of the most important requirements for malignant transformation to take place. Over-expression or inappropriate activation of growth-promoting signals by oncogenes can potentiate a cancerous state. Therefore, cell surface receptors that transmit growth stimulatory signals into the cell are targets of deregulation in cancer. For example, receptor over-expression such as epidermal growth factor receptor (EGFR) in stomach, brain and breast tumours [6], enables cancer cells to become over-responsive to ambient levels of growth factors (GF), which may not normally trigger cell proliferation. Equally, mutations in growth factor receptors can alter them to become constitutively activated in the absence of ligands. Alternatively, cancer cells can alter the extracellular matrix receptors or integrins they express, in favour of those that transmit pro-growth signals [7] or cause structural alterations to proteins downstream of ligand-activated growth factor receptors and integrins, such as mutant Ras proteins which are constitutively activated to release mitogenic signals [8]. 

 A second important characteristic is insensitivity to anti-growth signals. Within normal cells the potential to proliferate is held in check by the absence of soluble growth inhibitors found on the cell surface or in the extracellular matrix. Anti-growth signals can block proliferation by two mechanisms; cells can be forced out of the proliferative cycle and held in a quiescent state (G0) and prevented from entry into the cell cycle or they can undergo terminal differentiation into a state where they permanently lose their potential to proliferate.  Most normal cells respond to anti-growth signals, which govern the transit from G1 to S phase. Many of the anti-proliferative signals are mediated through the retinoblastoma protein (pRb), a key tumour suppressor protein that is dysfunctional in many human cancers [9]. The function of pRb can become disrupted through several mechanisms including genetic mutations of the pRb protein itself, or its inactivation by other oncoproteins that render it unable to interact with E2F transcription factor. Normally functioning pRb controls expression of a wide spectrum of genes essential for progression from G1 to S phase [10]. The antigrowth circuit converging onto pRb which is disrupted by changes in any number of signalling molecules, is a master regulator of the cell cycle [11]. 

Another feature of tumour cells is the ability to evade apoptosis. Many signals that elicit apoptosis converge on the mitochondria, which respond to pro-apoptotic signals by releasing cytochrome C. These are frequently mediated through the Bcl-2 family of proteins [12].  The p53 tumour suppressor protein is considered a ‘guardian of the genome’ as it has a critical role in the regulation of the cell cycle and apoptosis in response to DNA damage [13]. As a transcription factor, it is central in transcriptional activation of a number of target genes, which are involved in regulation of the cell cycle. Mutations of p53 are seen in about 50% of all human cancers, and this is clearly an important mechanism for tumour cells to evade apoptosis. Another key signalling network is the PI3K–Akt signalling pathway, which has been shown to be required for an extremely diverse array of cellular activities. In particular, it has been shown to play a critical role in regulation of cell cycle progression and apoptosis [14]. Phosphatidylinositol 3-kinase (PI3K) regulates protein kinase B (Akt) function. This central mediator of PI3K activity regulates many of these important biological processes, including cellular proliferation and survival. Most importantly, this PI3 kinase–Akt pathway is deregulated in many human cancers [15], therefore highlighting the importance of this complex signalling network. 

In addition to the above three acquired capabilities, tumour cells are thought to deregulate an intrinsic ability of normal cells to limit their multiplication. This enables cancer cells to operate independently of the cell-cell signalling pathways described, and give them limitless replicative potential. This is thought to be achieved through telomere maintenance [16]. Normal cells have the capacity for approximately 60 – 70 doublings, and this can be indirectly measured by loss of telomeric DNA. Telomeres are composed of several thousand repeats of short, six base-pair sequence elements found at the ends of chromosomes, and these progressively shorten during each cell cycle, which eventually causes them to lose their ability to protect the ends of chromosomal DNA. Ultimately, the unprotected chromosomal ends participate in end-to-end fusion, almost invariably resulting in death of the affected cells. Conversely however, tumour cells have the capacity to maintain their telomeres at a length above a critical threshold, which in turn permits unlimited replication.     

Another important feature for cancer formation is sustained angiogenesis. Angiogenesis is regulated by many endogenous factors. However, tumours can shift the balances between angiogenic regulators, through altered gene transcription of angiogenesis-initiating signals. For example, many tumours have increased expression of vascular endothelial growth factor (VEGF), while others show down-regulation of endogenous angiogenesis inhibitors such as thrombospondin-1 [17]. 

Finally, tumours have the capacity to induce tissue invasion and metastasis. These are very complex processes which require strategies to change the physical interaction of cells with their microenvironment and also activation of extracellular proteases [18]. Many classes of proteins are involved in cells tethering to their surroundings. These include cell-cell adhesion molecules (CAM) and integrins. Changes in CAM [19] and integrin [20] expression are evident in invading and metastatic cells. In addition, mutations in extracellular protease and protease inhibitor genes are also important in tumour invasion and metastasis [21].

These six essential alterations in cell physiology are universally recognised to be fundamental hallmarks in the process of tumourigenesis. More recently however, an additional seventh additional mechanism has been reported, namely cancer-related inflammation (CRI) [22]. The tumour microenvironment encompasses many inflammatory components that contribute to proliferation and survival of malignant cells. These include infiltration of white blood cells, tumour-associated macrophages and a plethora of cytokines eg. TNF, IL–1, IL–6, and chemokines eg. CCL2 and CXCL8 [22]. It is believed that their role in CRI may contribute to the genetic instability of cancer cells, and this may represent an additional seventh hallmark of cancer.
 
The molecular basis of each of these essential, acquired capabilities of cancer is common to many if not all malignancies, and therefore represents potential targets for cancer gene therapy. 

1.1.3 Cancer Gene Therapy
In 2003 the Government of the United Kingdom published the Genetics White Paper “Our inheritance, our future – realising the potential of genetics in the NHS” which defined gene therapy as “the deliberate introduction of genetic material into patients’ cells in order to treat or prevent a disease” [23]. This was a milestone in recognising the importance of gene therapy, which significantly increased funding in the field [24]. Gene therapy research was originally directed at monogenic disorders, with a single identifiable genetic defect. The initial focus was on disorders such as Severe Combined Immunodeficiency Disease (SCID), cystic fibrosis and haemophilia. 

More recently attention in gene therapy research has moved towards cancer, with the realisation that it too is a genetic disease. Many genetic alterations are involved in the transformation of a normal cell into a neoplastic one. The two main gene groups involved in cancer development are oncogenes and tumour suppressor genes, and these have been obvious target candidates for novel gene therapy strategies. More recently, our understanding of cancer has led to the realisation that tumours are in fact immunogenic. Therefore, newer anti-cancer therapeutics has been aimed at boosting the immune response against cancerous cells, through regulation of immuno-modulatory genes  [25]. The advent of new technologies in molecular biology and immunology has enabled great advances in our understanding of cancer. This along with the need for novel therapeutic agents has lead to significant progress in the field of cancer gene therapy over the past 20 years. 

Most encouragingly, the first gene therapy agent has now become available for patients with head and neck squamous cell carcinoma (HNSCC) in China. It is a p53 replacement therapy, in the form of Gendicine™ from Schenzhen SiBono GenTech (ShenZhen, Guangdong Province, China). The intra-tumoral injection is based on a replication-incompetent adenovirus in which the E1 region is replaced by a ubiquitous Rous sarcoma virus (RSV) promoter driving the tumour suppressor gene p53. So far, the use of this agent has been limited to head and neck cancer patients, who have a particularly high prevalence of p53 mutations, in the order of 50–69% [26], [27]. More recently, oncolytic viruses have also been developed as a new approach for the treatment of cancers that are resistant to standard therapies. The use of oncolytic replicating viruses and their interactions with both the tumour cell and host immune response, has been extensively studied within our group [28], [29], [30].
 
Although there are many other gene therapy agents being tested in clinical trials, they are not as of yet commercially available. Nevertheless, the availability and use of Gendicine, is in itself is very encouraging for the future scope of cancer gene therapy. In order to improve the outcome of cancer patients, the focus of future cancer gene therapy studies will need to identify potential therapeutic target genes that both significantly affect the behaviour of tumour cells and also impact on the prognosis of cancer patients. 

This study will explore the clinical and biological implications of ΔNp63α in cancer, with a view to its potential for novel gene therapy strategies. In order to investigate this, two solid tumours that are suitable models for cancer gene therapy, head and neck squamous cell carcinoma and pancreatic carcinoma, will be used. Both suffer from a lack of improvement of survival over the past three decades and patients with these diseases are in desperate need of alternative treatments.

HNSCC is an ideal model for cancer gene therapy as it generally progresses in a predictable manner, with a primary tumour followed by local lymphatic metastases to cervical lymph nodes, with distant metastatic disease only in advanced cases. HNSCC tumours are mostly easily accessible and are therefore amenable to repeated biopsy and intratumoural injection. Equally, pancreatic cancer is one of the most aggressive tumour types, with an extremely poor prognosis. Despite substantial efforts, the incidence and mortality rate of this cancer remain unchanged. Therefore, a better understanding of the factors that contribute to pancreatic cancer progression and prognosis is critical, in order to make an impact on the management of this disease. 


1.2 Head and Neck Cancer
Head and neck cancer encompasses all epithelial malignancies that arise from the mucosal surfaces of the nasal cavity and paranasal sinuses, salivary glands, thyroid and parathyroid glands, and upper aerodigestive tract including the oral cavity, pharynx and larynx. Most of these epithelial malignancies are squamous cell carcinomas of the head and neck (HNSCC). HNSCC represents 6% of all cancers and accounts for an estimated 650,000 new cancer cases and 350,000 cancer deaths worldwide every year [1]. It remains a significant cause of morbidity, as it can destroy the structure and function of vital organs involved in voice, speech, taste, smell and hearing, as well as result in a significant mortality rate. Approximately half of all patients with HNSCC have advanced stage disease at the time of diagnosis, with an expected 5-year survival rate between 10% and 40% [31]. 
Treatment of these solid tumours has traditionally been with a combination of surgery and chemo-radiotherapy. In Europe, despite combination treatment with these three modalities, the overall mortality is 50% [32]. With the overall survival of these patients remaining largely unchanged, HNSCC continues to be a treatment challenge, which in turn has highlighted the need for new approaches for diagnosis and treatment. The limited success of current treatment options has resulted in keen interest in novel treatments. Advances in our understanding of head and neck cancer genetics are encouraging for the potential of developing new cancer therapies and prognostic indicators of patient survival.

1.2.1 Epidemiology
Squamous cell carcinoma of the head and neck is a heterogenous disease with variable patterns of presentation and behaviour. The most important risk factors are tobacco and alcohol consumption [33], which have been implicated in 75% of HNSCC. There are some molecular data suggesting that the carcinogens found in these substances have a causal role. Carcinogens in tobacco and alcohol promote tumourigenesis by inducing genetic alterations, although the exact mechanisms remain obscure [34]. The prevalence and spectrum of p53 mutations are significantly greater in cancers in patients who smoke tobacco and drink alcohol [35]. 

Viruses have also been implicated in the pathogenesis of head and neck cancers. Most famous is the Epstein Barr virus (EBV) and the associated high incidence of nasopharyngeal carcinoma in the Far East [36]. Although most humans coexist with the virus without serious sequelae, a small proportion will develop tumours. EBV is a complex, enveloped DNA virus that belongs to the family of Herpes viridae. Following host cell infection, they can multiply in the nuclei and induce malignant transformation and cancer development. It uses its viral proteins, the actions of which mimic several growth factors, transcription factors and apoptotic factors to regulate diverse homeostatic functions to initiate malignancy [37].

There is also increasing evidence that oncogenic human papillomavirus (HPV) is another causal factor that is important in specific subsets of head and neck cancers [38]; about 25% of HNSCC contain HPV genomic DNA [39], with more than 50% of oropharyngeal carcinomas being HPV-positive [40]. HPV is papillomavirus that primarily infects transitional epithelial tissues [41]. HPV types 16 and 18 are the most frequent high risk types associated with HNSCC, with HPV 16 being the most commonly detected; it has been demonstrated in 90-95% of all HPV-positive head and neck cancer cases [42], [43]. High-risk oncogenic HPVs mediate their carcinogenic effect through two encoded oncoproteins, E6 and E7, which induce cellular transformation and dysregulation of cell cycle control, via inactivation of the tumour suppressor proteins p53 and pRB respectively. E7 interacts with and induces proteolytic degradation of pRb and E6 inactivates p53 by ubiquitin-mediated proteolysis [44].  It has been reported that patients who are HPV-positive are less likely to have tumours with p53 mutations and a better overall survival than HPV-negative patients. Also, absence of p16 mutations is another reported molecular hallmark of HPV-HNSCC [45]. Overall, HPV-positivity is a favourable prognostic factor in HNSCC [46], [47]. Therefore, detection of HPV in HNSCC has potentially significant therapeutic implications for this subset of tumours, with the prospect of developing vaccines targeting HPV oncogenic proteins E6 and E7.    

1.2.2 Molecular Pathogenesis
Head and neck cancer is thought to proceed in an orderly pattern, from benign squamous hyperplasia to dysplasia to carcinoma in situ to invasive carcinoma. Studies have shown that individual genomic aberrations develop at specific time points in disease progression (Fig. 1.2) [48].  

Fig. 1.2: Clinical progression of oral cancer; adapted from [48]. The histological progression of squamous epithelium from normal, to hyperkeratosis, to mild/moderate dysplasia, to severe dysplasia, to cancer and the sites of the most common genetic alterations identified as important for cancer development.

1.2.3 Molecular Biology
HNSCC is a heterogenous disease with complex molecular abnormalities. The genetic alterations observed in head and neck cancer are mainly due to oncogene activation and tumour suppressor gene inactivation, leading to deregulation of cell proliferation and death. These genetic alterations include gene amplification and overexpression of oncogenes, and mutations, deletions and hypermethylation of tumour suppressor genes. In addition, loss of heterozygosity in several chromosomal regions is frequently observed, suggesting that other tumour suppressor genes that have not yet been identified are likely to be involved in the tumourigenic process of head and neck cancers.   

1.2.3.1 Tumour suppressor genes
Loss of chromosomal region 9p21 is a very common genetic aberration, which is found in 70-80% of HNSCC cases, and is therefore one of the most common genetic alterations seen. Genes in the 9p21 region encode at least two proteins, p16 and p14ARF which are responsible for G1 cell cycle deregulation. Therefore, mutations in these genes permits uncontrolled cell growth, and this is mediated through both p53 and pRb pathways. These are both central pathways that are essential in cell cycle control, and there are many additional genes that also converge onto these pathways.
For example, inactivation of p16, also known as CDKN2A, is another tumour suppressor gene that is often inactivated [49], [50]. p16 inactivation is reported to occur early in squamous cell carcinogenesis and therefore thought to be an initiating event in neoplasia [51]. p16 transcribes cyclin-dependent kinase inhibitors, and inactivation leads to uncontrolled cell cycle progression, by preventing the association of CDK4 and CDK6 with D-type cyclins, and the subsequent phosphorylation of the pRb. 

Loss of chromosome region 3p is another early genetic event in HNSCC [52]. The specific locus responsible for the tumour suppressor phenotype of 3p remains uncharacterised. However, one region within 3p contains the fragile histidine triad gene (FIHT), a putative tumour suppressor gene, which is inactivated in a small proportion of HNSCC. However, the significance and role of genes mapped to 3p in carcinogenesis remains unknown.

As mentioned above, some of these genetic alterations converge onto two fundamental and well characterised cell signalling pathways, namely pRb and p53. The retinoblastoma gene located at chromosome 13q14, encodes a key tumour suppressor gene which is centrally involved in cell cycle control [53]. Hypophosphorylated pRb binds to and inactivates the transcription factor, E2F, required for cell cycle progression. Loss of pRb activity can therefore cause unchecked cell growth. The signalling circuits that converge onto the pRb pathway however, are diverse. 
  
Dysfunction in the p53 tumour suppressor gene is the most well documented genetic alteration associated with cancer. p53 protein is a transcription factor which plays a central role in mediating cellular responses to cytotoxic stress by contributing to both cell cycle arrest and programmed cell death.  p53 production is therefore normally increased in response to cellular insults or DNA damage, and acts to induce cell cycle arrest at the G1/S junction, or initiate cell death by apoptosis [54].  During carcinogenesis, loss of p53 function leads to inappropriate cell growth and increased cell survival. In head and neck cancer, loss of heterozygosity of 17p and point mutations of p53 are seen in approximately 50% of cases [55]. Most of these mutations occur late in the progression from epithelial dysplasia to invasive carcinoma [56], and therefore p53 mutations may contribute to tumour aggressiveness.

1.2.3.2 Oncogenes
Cyclin D1 is frequently upregulated in head and neck cancers. The gene is located at chromosome 11q13. Amplification of this site resulting in overexpression of cyclin D1, is observed in about 30-60% of HNSCC, and is associated with invasive carcinoma [57]. Cyclin D1 is a critical cell cycle regulatory protein that drives the cell cycle from G1 to S phase by indirectly phosphorylating and inactivating pRb. In HNSCC, cyclin D1 overexpression has been associated with higher stage, nodal spread, poorer response to therapy and reduced survival [58], [59]. 

Epidermal growth factor receptor (EGFR) is another oncogene frequently associated with HNSCC. The EGFR gene located on chromosome 7p12 is upregulated in more than 90% of HNSCC [60] and correlates with poor prognosis. EGFR is a member of the ErbB growth factor receptor tyrosine kinase family. This transmembrane glycoprotein therefore functions as a tyrosine-kinase receptor to which a number of ligands bind, including epidermal growth factor (EGF), transforming growth factor-α (TGF-α) as well as other growth-factors. This results in stimulation of tumour growth through both autocrine and paracrine pathways. One important target of EGFR is regulation of E-cadherin, a transmembrane glycoprotein essential for cell-cell interaction, through which it may contribute to tumour invasion and metastasis. 

Angiogenic regulators are also commonly altered in cancer. Of these, one of the most important is vascular endothelial growth factor (VEGF) and its receptors [61], which induce endothelial cell proliferation and survival. VEGF can be upregulated in HNSCC, and consequently this is reported to have some prognostic significance [62]. 





Pancreatic ductal adenocarcinoma (PDAC) constitutes over 90% of human pancreatic cancers. PDAC is the 5th most common cause of cancer death in the UK, and results in an estimated 227,000 deaths per year worldwide [1]. It is a lethal disease and notoriously difficult to treat, with surgical resection representing the only curative option. However, at present only 20% of patients present with early stage, operable disease [63]. Most patients present with advanced or metastatic disease, and are only suitable for palliative chemotherapy and radiotherapy, which do not result in significant long-term survival [64]. The lack of curative therapies has translated into a median survival time after diagnosis of about six months and an overall 5-year survival rate of less than 5% [65], thus underscoring a desperate need for improved therapeutic options and diagnostic tools. 

1.3.1 Epidemiology
A number of established risk factors that contribute to PDAC have been identified. These include advanced age, smoking and chronic pancreatitis  ADDIN EN.CITE [66-70]. Diabetes mellitus is also known to be closely associated with pancreatic cancer [71] although its precise relationship to the malignant process remains controversial.

The majority of pancreatic carcinomas are sporadic and only an estimated maximum of 10% are considered to be hereditary  ADDIN EN.CITE [72, 73]. Most researchers define familial pancreatic cancer (FPC) as families with two or more first-degree relatives with pancreatic cancer without having another inherited cancer syndrome [74]. Patients who inherit pancreatic cancer in an autosomal dominant fashion are at the highest risk, which can approach 50%  ADDIN EN.CITE [75, 76]. The causative mutations and genes responsible for FPC have not yet been identified.
In addition, a number of familial genetic syndromes have also been linked [77], [78]. These include hereditary non-polyposis colon cancer [79], Peutz-Jeghers syndrome  ADDIN EN.CITE [80, 81], familial breast and ovarian carcinoma (FOBC) [82], familial atypical multiple mole melanoma (FAMMM) [83] and familial adenomatous polyposis (FAP) [84]. Other inherited syndromes that predispose to pancreatic cancer are hereditary pancreatitis  ADDIN EN.CITE [85, 86], cystic fibrosis  ADDIN EN.CITE [87] and ataxia-telangiectasia (AT) [88].

1.3.2 Molecular Pathogenesis




Fig 1.3: Molecular progression model of pancreatic cancer [89].
1.3.3 Molecular biology
Recent advances have characterised multiple cytogenetic abnormalities which have been implicated in the complex process of pancreatic carcinogenesis. These include activation of oncogenes, deregulation of tumour suppressor genes and genome maintenance genes, upregulation of growth factors and growth factor receptor signalling pathways, and alterations in cytokine expression. 

1.3.3.1 Oncogenes
K-ras oncogene mutation is one of the commonest genetic alterations associated with pancreatic cancer, and is present in 75 - 90% of sporadic pancreatic tumours [90]. The gene is located at chromosome 12p13 and it encodes a 21kDa membrane-bound guanosine triphosphate (GTP)-binding protein involved in growth factor-mediated signal transduction pathways. Mutations in K-ras mostly occur at codon 12, but also occasionally at codon 13 and 61. Mutations result in impaired intrinsic GTPhosphatase (GTPase) activity of K-ras, resulting in it being locked in the constitutively active GTP–bound form. In this activated state, it enables activation of downstream signalling cascades which result in a permanent loss of G1 arrest and enhanced cellular proliferation. There are a number of additional implicated oncogenes that regulate the G1 to S checkpoint of the cell cycle. In response to mitogenic signals, cyclin D is upregulated which in turn activates cyclin D-dependent kinases 4 and 6 (CDK 4 and 6). This leads to phosphorylation of pRB, resulting in the release of transcription factor E2F, therefore inducing the expression of genes needed for DNA synthesis. 

There is no significance difference in the prevalence of K-ras mutations at different stages of the disease [91], and they are often also found in benign lesions of the pancreas [92], suggesting that activation of this oncogene is an early event and perhaps involved in initiation of carcinogenesis. 

1.3.3.2 Tumour suppressor genes
The CDKN2/MTS1/INK4A tumour suppressor gene is located at chromosome 9p21 and encodes the p16 protein that functions as a regulator of the cell cycle. Inactivation of p16 occurs in almost 90% of pancreatic cancers [93]. Loss of nuclear p16 appears to be a relatively early event in the progression of pancreatic cancer, and is seen in 30% of PanIN-1, 55% of PanIN-2 and 71% of PanIN-3 lesions [94]. In pancreatic cancer, p16 can be inactivated by different mechanisms including homozygous deletions (~40%), point mutations (~40%) and epigenetic silencing by promoter hypermethylation (10-15%). INK4 belongs to the family of Cdk (cyclin-dependent kinase) inhibitors, which block the phosphorylation of retinoblastoma (RB) protein by cyclin-dependent kinases (CDK4 and CDK6) [95] and play a key role in the G1 checkpoint in the cell cycle. 

The p53 tumour-suppressor gene is located on the short arm of chromosome 17 and is inactivated in 50% to 70% of PDAC cases  ADDIN EN.CITE [96]. The p53 transcription factor is normally maintained at very low levels as a result of its interaction with the HDM2 (human homologue of MDM2). Studies have demonstrated the nuclear accumulation of mutated p53 in advanced PanIN-3 lesions. Therefore loss of p53 function is considered to be a late event in the progression model [97], [98]. 





The p53 gene has now gained its status as the archetypal tumour suppressor gene, as it is the most frequently mutated gene in human cancers [103]. As a ‘guardian of the genome’ it has a critical role in the regulation of the cell cycle and apoptosis in response to DNA damage [13]. Its chromosomal locus is located at chromosome 17p13. The p53 protein is a sequence specific transcription factor that regulates the expression of genes involved in cell cycle arrest or apoptosis, in response to genotoxic damage or cell stress [104]. It therefore functions in carcinogenesis by initiating G1 arrest. Key p53 transcriptional target genes include WAF1/p21 which regulates cyclin-dependent kinase activity, MDM2/HDM2 whose protein product is a negative regulator of p53 and 14-3-3 σ (a regulator of G2/M progression). p53 also regulates apoptosis-related genes such as BAX which is a pro-apoptotic, Bcl-2-related protein and genes involved in generation of reactive oxygen species. 

The normal p53 protein which undergoes rapid degradation, has a very short half-life of 20 minutes, and is therefore usually present at extremely low levels within cells. However, in response to stress such as DNA damaging agents or chronic mitogenic stimulation, p53 is transiently stabilised and activated. p53 activation leads to inhibition of cell cycle progression, induction of senescence, differentiation or apoptosis [105]. Therefore, p53 is of vital importance in maintaining the integrity of the genome and controlled cell growth [54]. This activity is central to its role as a tumour suppressor. Most human tumours exhibit inactivation of p53, either through direct mutation or deletion of p53 itself, or through disruption of regulatory pathways that are essential for p53 function. 

Mutational analysis in human cancers indicate that TP53 mutations are mainly missense mutations of the central domain of the coding region (exons 5-9) [106]. It is reported that after mutation in one p53 allele, the remaining wild type allele is deleted and therefore the mutant phenotype is expressed [107], [108]. In addition to gene mutations, p53 function can also be inactivated by several other mechanisms. Of these, the p53-Mdm2 paradigm is one of the most well studied relationships between a tumour suppressor gene and an oncogene. Mdm2 is an important negative regulator of the p53 gene; it is transcriptionally activated by p53 and in turn represses p53 transcriptional activity through direct binding. By binding directly to MDM2, p53 is protected from MDM2-mediated proteosomal degradation. Thus the levels of p53 increase and regulate a transcription response leading to cell cycle arrest or to apoptosis [109].  Both these genes are subject to complex post-translational modifications, which in turn dictate their stability and activity [110].

Germline mutations in p53 are found in Li-Fraumeni syndrome, a tumour-prone disorder in which affected individuals are predisposed to tumours of the brain, breast, bone and adrenal cortex [111]. p53 knockout mice are also reported to develop normally but predisposed to early onset tumours, in particular thymic lymphomas, sarcomas and testicular tumours [112]. Genetic studies have confirmed that p53 is mutated in approximately 50% of all human cancers. 

1.4.1 Apoptosis by p53
The most well understood activity of p53 is as a transcription factor that binds to the promoters and introns of target genes, and recruits the basal transcriptional machinery to activate expression of those genes. To date, hundreds of p53 target genes have been identified [113]. One of the most well documented functions is its transcription of p21 gene, which interacts with a cell division-stimulating protein (cdk2). When p21 is complexed with cdk2, the cell cannot pass through to the next stage of cell division. Mutant p53 can no longer bind DNA in an effective way, and as a consequence the p21 protein is not made available to act as the 'stop signal' for cell division. Thus cells can divide uncontrollably, and form tumours. Once bound to these promoter regions, p53 recruits general transcription factors as well as histone acetyltransferases (HATS), such as CREB-binding protein (CBP)/p300. The p300/CBP family comprises transcriptional adaptors for p53, modulating its checkpoint function in the G1 phase of the cell cycle and its induction of apoptosis [114]. 

1.4.2 p53 superfamily
Over a decade after the identification of p53, two p53-related genes, p63 and p73 have been identified [115], [116], [117]. The three members of the p53 family share very significant homology at both the genomic and protein level, which led to initial speculation that they may play an analogous role in human tumours [118]. However, there is in fact a much more complex picture of the contribution of p63 and p73 to human cancer, and this is largely due to differences in their transcriptional regulation and expression profiles.

1.4.2.1 p53 superfamily structure
All three family members possess several conserved protein domains (Fig 1.4). These include a transactivation domain (TAD), a central DNA-binding domain (DBD) and an oligomerisation domain (OD). In addition, p63 and p73 contain long C-termini [118]. 





Fig 1.4: Gene architecture of p53 family; p53, p63 and p73 are represented with their respective functional domains. 


By determining the three-dimensional solution structure of the p73 C-terminus, it has identified that this region contains a sterile alpha motif (SAM) [119]. This SAM domain and a post SAM domain has subsequently been identified as present in p63 also [120]. The SAM modulates protein-protein interactions and the transactivation inhibition [121]. This transactivation inhibitory domain can interact with the TA domain and mask the residues that are crucial for transactivation.

The highest degree of homology between the three genes is observed in the DBD, which suggested that these genes may regulate transcription of a common subset of target genes. There is 60% amino acid identity between p53 and p73, and 63% identity between p53 and p63. Interestingly, there is greater homology between p63 and p73 (~85%). 

All three genes give rise to multiple protein products resulting from both alternative promoter usage and alternative mRNA splicing (Fig 1.5). They all encode two primary transcripts that are controlled by separate promoters P1 and P2 (Fig 1.5). The P1 promoter of each gene is embedded in a non-coding region of exon 1. The P2 promoter for genes p63 and p73 is located in intron 3, whereas the P2 promoter of p53 is located in intron 4. Transcripts generated from the P1 promoter produce proteins that include the TAD. In contrast, transcripts generated from the P2 promoter result in the absence of TAD, and are therefore designated ΔN-terminal variants. However, for p73, 5’ exon splicing within the P1 promoter transcripts generates further protein products that lack the TAD. Collectively, all the ΔN-terminal variants for the p53 superfamily are regarded as dominant-negative versions, as they can occupy promoter-binding sites but fail to transactivate gene expression. However, they can induce transcativation of p53-independent target genes, by the use of a unique N–terminal sequence which they possess. 









Fig 1.5: Structure of p53 family members - transcription units, adapted from [122]. Numbered boxes indicate exons, and black shading denotes untranslated sequences.The approximate regions encoding the transactivation (TA) domain (light blue), DN-specific region (green), DNA-binding domain (red), oligomerization domain (yellow), sterile alpha motif (SAM, grey), and post SAM domain (orange) are indicated. Distinct transcription start sites are indicated by arrows. N-terminal alternative splicing for p53 and p73 are indicated by dotted lines, and C-terminal splicing events for all p53 family members are indicated by solid lines and Greek letter designation.

Although the structural homology shared between the members of the p53 superfamily would suggest that their products would share similar functions as transcription factors, the actual spectrum of target genes activated between them is quite different. They also exhibit distinct biological functions, which have been supported from genetic studies in mice. Their role in the development of cancers is still not yet clearly defined.

1.4.2.2 p53 superfamily and cancer
p63 and p73 map to two regions within the human genome that are often altered in cancers [123]. This was suggestive that they would have tumour-suppressive properties analogous to p53. However, characterisation of these proteins as tumour suppressors has not been straightforward, as there are some salient differences in function between them (Table 1.1). 

Knockout mice studies has shown conflicting reports for the effect of p63 and p73 on tumour development, as compared with p53, thus adding to the difficulties in defining p63 and p73 as tumour suppressor proteins. It is well reported that transgenic mice expressing mutant p53 or p53-/- are highly prone to both spontaneous and induced tumours [112]. In contrast, p73-knockout mice do not develop spontaneous tumours [124] and p63-deficient mice show developmental abnormalities but are also not tumour-prone [125]. 

p53 mutations occur in about 50% of all human cancers. However, p63 and p73 mutations occur rarely [126]. Furthermore, altered expression of p63 and p73 isoforms with widely divergent biological properties is commonly observed, thus adding to the complexity in elucidating their contribution in human cancers.


Table 1.1: Comparison of p53 gene family.

	p53	P63	p73
Expression Pattern	Ubiquitous expression	Cell- and tissue- specific expression	Cell- and tissue- specific expression
Developmental function	No role in normal development	Essential in stem cell biology of epitheliaregulates tissue-specific differentiation	Required for CNS development in specific neuronal structures
Cell Cycle Regulation	Fundamental role in stress / DNA damage response	Moderate role in cell cycle control	Moderate role in cell cycle control 
Genomic status in malignancy	Frequently mutated	Rarely mutated;often amplified	Rarely mutated; often overexpressed










Fig. 1.6: Human p63 [128]. (a) Schema of the human p63 gene structure: alternative splicing (α, β and γ) and alternative promoters (P1 and P2) are indicated. (b) p63 protein isoforms: TAp63 proteins encoded from promoter P1 contain the conserved N-terminal domain of transactivation (TA). ΔNp63 proteins encoded from promoter P2 are amino-truncated proteins containing an N-terminal domain different from TAp63 proteins. Numbers indicate the exons encoding p63 protein isoforms.


The TAp63 isoforms are able to bind to DNA through p53-responsive elements, as a consequence of the homology with p53 in its DNA-binding domain. This enables TAp63 isoforms to transactivate many p53 target genes involved in cell cycle arrest, thus resulting in them being described as ‘p53-like’. However, more recent studies have shown that TAp63 proteins can also bind to DNA response elements that differ from p53RE. Therefore, these DNA regions respond to transcription by p63 alone, but not p53 [128], [130], [131]. The effectiveness of transactivation of target genes is modulated by the C–terminal end of the TAp63 isoforms. The TAp63γ isoform most closely resembles full length p53. It is the most potent transcriptional regulator and inducer of apoptosis, as it contains the transactivation domain and lacks the inhibitory domain present in the alpha isoforms [120], [129]. Gene profiling microarray has been used to analyse the gene expression profiles induced or downregulated by p63 isotypes [132]. This revealed that approximately 40% of target genes induced by TAp63γ were p53-responsive targets involved in apoptosis and tumour suppression [132].

The ΔNp63 isoforms can also bind DNA through p53RE, but in doing so they exert a dominant negative effect over p53 and p53 target genes, including TAp73 and TAp63 isoforms. This effect is either by competing for p53-responsive DNA-binding sites, or by direct protein interaction [128, 133], [134]. However, ΔNp63 isoforms have also been shown to activate specific target genes that are not induced by TA isoforms [135], [136], through its short transactivation specific N–terminus.  Therefore, the TAp63 and ΔNp63 isoforms can regulate a number of genes with opposing regulatory effects.

Finally, all α-isoforms contain a 27kDa C-terminal region that drastically reduces their activity and is of clear biological importance, since cells with deletions in this C-terminus have phenotypes very similar to cells with mutations in the DNA-binding domain [120], [137]. The sterile alpha motif (SAM) domain and post-SAM domain is necessary and sufficient for transcriptional inhibition, and acts by binding to a region in the N-terminal transactivation domain of p63. It is therefore a protein–protein interaction domain, which interestingly is also implicated in a wide variety of proteins implicated in development.

1.5.1 Regulation of p63 stability
ΔNp63 isoforms are far more stable than the TA isoforms, as the half-life of TAp63 isoforms is approximately six minutes in vitro, as compared with a half-life of more than five hours for ΔNp63 isoforms [138]. This may suggest that p63 protein half-life depends on the amino terminus. Furthermore, the specific binding activity of TAp63 maybe essential for its protein stability as disease related DNA binding mutants of TAp63 are very stable. For example, MDM2 binds TAp63, but it is unlikely that MDM2 is the E3 ubiquitin ligase responsible for its degradation, as ectopic delivery of MDM2 has no significant effect on TAp63 levels [139]. However, p63α and p63γ are exported from the nucleus to the cytoplasm when co-expressed with MDM2, suggesting that MDM2 can inhibit the apoptotic function of p63 by removing it from the nucleus, rather than directing its degradation [139]. 

The C–terminal may also be important in the stability of p63 isoforms, since TAp63α exhibits a longer half-life than TAp63γ [140]. This stability maybe explained by the post-SAM domain present in the α forms, which could protect them from degradation [120]. 

ΔNp63 can also be degraded by a proteosome-dependant pathway. Upon cisplatin exposure, this degradation has been shown to involve stratifin (14 – 3 - 3σ) for nuclear export and RACK 1 as E3 ubiquitin ligase [141]. TNF–α has also been shown to induce ΔNp63α degradation through the ubiquitin–proteosomal pathway [142]. Furthermore, ΔNp63α is critical in maintaining epidermal homeostasis but the factors that contribute to this are only just emerging. Tumour necrosis factor–α (TNF–α) is an important multifunctional cytokine that has been implicated in regulating epithelial proliferation in normal tissues during chronic inflammation or wound healing, and also in cancer. Lee et al showed that TNF–α induces ΔNp63α degradation through the ubiquitin–proteosomal pathway as well as caspase-dependent pathways, and this degradation seems to require activation of NF-κB [142]. 

Only a few post-translational modifications have been described to date. Some phosphorylations on Ser/Thr residues have been reported. Upon genotoxic stress, they result in the stabilisation of exogenous TAp63α and γ isoforms [143], and accelerated degradation of ΔNp63α [144].
    
1.5.2 p63 expression in normal human tissues
Significant differences between p53 and p63 importance in normal development were revealed by the phenotypes observed from knockout mice studies. p53-null mice are phenotypically normal and viable, albeit with a greater predisposition to malignancy.  In contrast, p63 null-mice have severe developmental abnormalities of the skin, limbs, mammary, prostate and other epithelial tissues [145], [146]. Ultimately, they are not viable, thus underpinning an essential developmental role for p63 in the regulation of differentiation and proliferation.

p63 is absolutely essential for limb formation and epidermal morphogenesis, including in the formation of adnexa. It is expressed in a highly restricted pattern during embryonic development. Its expression is first detected within the primitive ectoderm, which gives rise to the epidermis as well as epithelial appendages including the mammary gland, prostate, teeth and sweat glands. p63 is also expressed in the apical ectodermal ridge, which is a specialised cluster of ectodermal cells required for inductive events for limb formation [145], [146].  p63 is essential for the development of most tissues in which it is expressed,  as supported by knockout mouse studies described above. 

In embryonic epidermis, p63 is the molecular switch for initiation of an epithelial stratification programme [147]. In postnatal epidermis, p63 expression is detectable in the ‘stem’ cell types; it is restricted to the nuclei of basal and myoepithelial cells of normal tissues and is also found in certain populations of basal cells in glandular structures of prostate, breast and bronchi [129], [148]. Specifically, p63 expression in the myoepithelial breast cells is considered to be a marker for these cells in normal breast tissue [149], [150]. p63 expression in prostate is restricted to basal cells, thereby making it an excellent diagnostic marker in prostate cancer, as most prostate cancers and pre-invasive prostate intraepithelial neoplasia lesions are devoid of basal cells and have therefore lost p63 expression [151].

Heterozygous point mutations of p63 in humans are associated with a number of syndromes with ectodermal dysplasia, orofacial clefting and limb malformations as key characteristics [138], [152].   To date, there have been five rare autosomal dominant developmental disorders with variable genotype–phenotype correlation described, and two non-syndromic disorders (Fig. 1.7)  [152].  
                                 

Fig. 1.7: p63-associated developmental disorders [152]. Various combinations of ectodermal dysplasia, orofacial clefting and limb malformations are the hallmark of p63–associated syndromes. EEC syndrome is the prototype of these syndromes and together with LMS shows all the hallmarks. ADULT syndrome patients do not show orofacial clefting, and AEC and RHS patients do not show limb defects. Non–syndromic limb defect condition (SHFM4) and non–syndromic cleft lip / palate (NSCL) are also caused by p63 mutations.


Electrodactyly–Ectodermal dysplasia Clefting (EEC) or the related but distinct Ankyloblepharon–Ectodermal dysplasia Clefting (AEC or Hays Wells syndrome) was the first discovered. Almost all p63 mutations associated with EEC occur within the DBD. These EEC mutations affect all six major proteins and inhibit DNA binding of the TAp63 isoforms. Conversely, mutations in ΔNp63 proteins result in a loss of their dominant-negative effect on p53 and TAp63γ [153]. In contrast, p63 mutations in AEC occur in the SAM domain and therefore only affect the two α-isoforms. This results in a loss of interaction with apobec 1 binding protein-1 and subsequent failure to generate an alternatively spliced form of the fibroblast growth factor receptor–2, which is essential for epithelial differentiation [154]. This may account for the phenotype that is seen in AEC. There are three additional related human developmental syndromes associated with p63 mutation. These include Acro–Dermo–Ungal–Lacrimal–Tooth syndrome (ADULT), limb mammary syndrome (LMS) and Rapp–Hodgkin syndrome (RHS). These four developmental disorders however, extend the genotype–phenotype correlation [155].

Split Hand/Foot malformation type 4 (SHFM4) is a ‘pure’ limb malformation condition, thus without orofacial clefting or ectodermal dysplasia. This condition is caused by several p63 mutations which are dispersed through the p63 gene, which are thought to alter p63 protein activation and stability [152]. Another non-syndromic orofacial clefting type has also been linked to p63 gene, causing Non-syndromic cleft lip/palate (NSCL) phenotype [156]. 
 
Put together, these data clearly establish a fundamental role of p63 in normal development and more specifically, epithelial stem cell biology and in the apical ectodermal ridge of the limb bud. The exact role of p63 in stem cell biology however, remains unclear. There are some reports which suggest that p63 is required for the ectoderm to commit to epidermal lineages [145], [146]. Alternatively, it maybe that p63 is not required to commit but to maintain the stem cell pool and prevent it from differentiation [155], as p63 expression is lost as basal cells are lost as they withdraw from the stem cell compartment [157].   

During development of normal tissues, the expression profile is not the same for all the isoforms. Although mRNA for TAp63 is detectable during embryogenesis, the most abundant isoform expressed in basal cells of the epithelium is the N-terminal truncated ΔNp63 isoform (ratio approximately 100:1 of ΔNp63 to TAp63) [129]. This is also the predominant isoform that is expressed in many human cancers. 

1.5.3 p63 and cancer
p63 gene function highlights the tight link between developmental processes and tumourigenesis. With respect to its role in cancer, p63 markedly contrasts with p53, the achetypal tumour suppressor gene. p63 is rarely mutated in human cancers (<1%) [158], [159]. Infact, the p63 chromosomal locus is frequently amplified in squamous cell carcinomas [160], thus supporting a pro-proliferative or oncogenic role for p63. However, often there is no correlation between the amplification of the p63 gene and the expression levels of protein [161]. For example, some cancers have been identified as showing p63 overexpression associated with only a modest increase in TP63 copy numbers [160] This is partly attributed to the various post-translational modifications that this molecule undergoes [162]. Many tumours maintain p63 expression and it is frequently overexpressed in a wide spectrum of tumour types, however, the p63 isoform expressed in all cancers has not yet been determined (Table 1.2).

Table 1.2: p63 expression in human cancer.

Tissue / organ site	Variant p63 expressed	Comments	References
Breast cancer	ΔNp63	Overexpressed in subset of breast cancers	[149], [163], [164]
Bladder cancer	TAp63 & ΔNp63	TAp63: no change in expression between tumour and normalΔNp63: only in tumours	[165], [166]
Urothelial cancer	TAp63 and ΔNp63	ΔNp63 expression correlates with more aggressive phenotypes	[167]
Cervical cancer	Not determined 	Protein expression	[168], [169], [170],  [122]
Uterine cancer	Not determined	Protein expression	[171]
HNSCC	TAp63 and ΔNp63	Predominantly ΔNp63 (TAp63 rare)	[160], [172], [173]
Lung cancer	TAp63 and ΔNp63	Predominantly ΔNp63 in tumour tissues	[160], [174], [175], [176]
Prostate cancer	ΔNp63	Protein expression	[151], [177] 
Oesophageal SCC	TAp63 and ΔNp63	ΔNp63 expression in squamous cell carcinoma	[161], [178], [179], [180], [181]
Gastric cancer	TAp63 and ΔNp63	Protein expression	[182]
Pancreatic cancer	Not determined	Protein expression	[183], [184]


p63 is a target of genomic amplification and overexpression of its protein in more than 80% of  primary head and neck squamous cell carcinomas (HNSCC), as well as other squamous epithelial malignancies including lung, nasopharyngeal, oesophageal and cervical cancers [160], [168], [178], [185], [174]. Several groups have reported increased wild-type p63 mRNA levels that correlate with an increase in p63 gene copy number in squamous cell carcinomas of the lung and head and neck [160], [175]. However, in other cases, overexpression of p63 appears to involve mechanisms independent of genomic amplification [186]. Therefore, there is still some controversy as to whether p63 is the targeted gene driving amplification of this locus. 

Recent reports have used quantitative isoform-specific reverse transcription polymerase chain reaction (RT-PCR), with immunoblot analysis to demonstrate that ΔNp63α is the predominant p63 isoform expressed in many squamous cell carcinomas. This overexpression of ΔNp63α supports its role as an oncogene. One exception to this has been the p63 expression observed in bladder tumours. One study has shown that ΔNp63 is overexpressed in the majority of invasive bladder carcinomas [165], while others have found that a subset of these cancers demonstrate loss of p63 expression and this is associated with progression to invasion and metastasis, and a poor prognosis [166], [167]. 

1.5.3.1 Contribution of p63 to tumourigenesis
A complex picture emerges when trying to define the precise contribution of p63 to tumour development. Much of this complexity stems from the recognition that both TA and ΔNp63 isoforms are expressed in many human tumours. TAp63 isoforms, like p53 are known to exhibit tumour-suppressive properties and upregulation of ΔNp63 is a common mechanism for inactivation during tumourigenesis.

1.5.3.1.1 Competition between p53 family members
Both physical and functional interactions among p53 family members have been demonstrated in tumour-specific contexts, through two main mechanisms. Firstly, competition for the p53 family binding sites within promoters of shared downstream target genes is one likely mechanism [133], [187]. Secondly, direct physical interactions of the different isoforms is known to alter the complex required for DNA binding and transcriptional regulation [188]. In ectopic expression studies, heteromeric complexes have been demonstrated between different isoforms of the same gene, such as TAp63 and ΔNp63 [188], where the ΔN isoform acts as a potent inhibitor of transactivation by the TA isoform. Consistent with these findings, endogenous complexes have also been demonstrated between ΔNp63 and TAp73 [189].  Wild-type p53 binds p63 and p73 with much lower affinity than p63 and p73 bind one another [190] 

1.5.3.1.2 p63 regulation of proliferation and differentiation in tumours
In normal basal epithelial cells, ΔNp63α promotes cell proliferation through regulation of shared p53 target genes, such as p21, as well as other likely pathways [191]. The ability of ΔNp63α to enhance proliferation  and suppress cellular senescence during development suggests a possible contribution of p63 early in tumourigenesis [192]. The expression of ΔNp63α is closely linked to the undifferentiated state in basal epithelial cells, and ΔNp63α expression is lost in normal cells as they become increasingly differentiated [193]. The mechanism through which p63 may regulate differentiation is still unknown, however, there is some evidence that it maybe through p63 regulation of p53-independent genes required for keratinocyte differentiation, such as loricrin and involucrin [194]. p63 could also regulate p53-independent effects on adhesive signalling, Notch activation and pRb phosphorylation [195], [196], [197]. 

p63 is also essential for the differentiation of transitional urothelium and is expressed in normal bladder urothelium. p63 expression is lost in most invasive bladder cancers [166].

1.5.3.1.3 Regulation of apoptosis by p63
Like p53, p63 protein levels are also increased when cells are exposed to DNA-damaging agents [198]. Increased p63 protein is not the result of increased transcriptional activation of p63 gene, but more likely due to post-translational modifications of this protein [198], [143]. 










It is well established that the ΔNp63 isoforms exert a dominant-negative effect over p53 and p53 target genes, either by competitive binding to the RE of target genes or by direct interaction. Of these, ΔNp63α appears to be the more potent dominant-negative inhibitor of all the ΔNp63 isoforms. This maybe due to the presence of the SAM and post-SAM domains which are able to recruit other proteins or fold up and inactivate the TA domain [120]. However, in addition to the dominant negative functions of ΔNp63α, it is also now recognised that the ΔNp63 isoforms contains a short unique transactivation domain that is involved in activating multiple target genes by directly binding to their promoter regions [201], [202]. Wu et al used gene expression profiling to compare downstream target genes for TAp63α and ΔNp63α, which confirmed that the Hsp70 gene was more significantly upregulated by the ΔNp63α isoform [136]. Further analysis has shown that this transactivation of Hsp70 by ΔNp63α is structure-related, and interacts with the Hsp70 promoter [202]. Helton et al also characterised several functional domains that regulate ΔNp63 transactivation potential [201]. They identified this activation domain to include 14 unique ΔN residues, including a PXXP motif [201].

1.5.4.1 ΔNp63α expression in human cancer
Many p63 isoforms are produced in squamous carcinomas, and it is the ΔNp63 form which is predominant in most (Table 1.2), thus supporting its role as an oncogene. This has been confirmed for nasopharyngeal tumours; in 25 primary nasopharyngeal carcinomas, all tumour cells over-expressed predominantly ΔNp63, which in normal nasopharyngeal epithelium is restricted to proliferating basal and suprabasal cells [172]. Similarly, in oesophageal squamous cell carcinomas, ΔNp63 was again the major isotype found to be expressed, with p63 staining restricted to basal and suprabasal cell layers in normal oesophagus [178]. Upregulation of ΔNp63 was also found in 30 of 47 bladder cancers [165]. Interestingly, TAp63 was found to be downregulated in 25 of the total 47 tumour examined. However, another study on 160 transitional cell carcinomas examined this relationship more closely [167]. Koga et al found that loss of p63 expression in transitional cell carcinomas correlated with a progressive loss of urothelial differentiation, associated with advanced stage and grade [167]. Furthermore, p63 is expressed in a minority of breast carcinomas (mainly ductal carcinomas) and is not expressed in invasive carcinomas [163]. 

1.5.4.1.1 ΔNp63α effects on tumour biology
The ability of cancer cells to invade is an essential component of metastasis, which is dependent on several factors. There is now unfolding evidence that p63 may be implicated in this function. ΔNp63α expression has been shown to decrease cell motility and cell invasion of squamous cells [203], [204]. 

TGF–β signalling is central to tumourigenesis. TGF–β ligands act as tumour supressors in early stage tumours but paradoxically become potent pro–metastatic factors in advanced cancers. p63 has recently been implicated in the metastatic pathway [205]. It has been shown that p63 is inactivated by TGF–β, which can induce metastasis in the presence of oncogenic Ras, which is required to phosphorylate mutant p53 so that it can form a mutant p53/Smad complex. This mutant p53/Smad complex opposes p63 to empower TGF–β induced metastasis [205] . 

The zinc finger transcription factor SNAIL has also been shown to promote invasion by repressing multiple proteins including ΔNp63α [204]. More recently, it was reported that ΔNp63α induces Id-3 which also suppresses invasiveness [206]. It was reported that ΔNp63α positively regulates inhibitor of differentiation-3 (Id-3) expression [206]. Id is a dominant-negative regulator of E2A which is a transcriptional repressor of E-cadherin. Put together, these data collectively support a role for ΔNp63α in suppressing invasion. Furthermore, Kommagani et al studied the regulation of vitamin D receptor (VDR) by ΔNp63α [207]. The active form of vitamin D has been shown to inhibit the invasiveness of prostate cancer cells through VDR [208]. They have shown that ΔNp63α induces VDR, through direct transcriptional activation, and in doing so inhibits cell migration and invasion [207]. Therefore, there is growing evidence that ΔNp63α does indeed play a functional role in cancer cell migration and invasion, but this still needs to be further explored and characterised across different tumour models. 

1.5.4.1.2 ΔNp63α effects on chemosensitivity
It has previously been reported that genotoxic stress agents induce phosphorylation and decreased ΔNp63α expression in head and neck squamous carcinoma cells [141]. Upon cisplatin exposure, stratifin has been found to bind to phosphorylated ΔNp63α and mediate its nuclear export into the cytoplasm, where it is targeted by RACK 1 into proteosomal degradation pathway [141].  In addition, ΔNp63α protein levels have been suggested to be an important predictor of cells’ responses to such platinum based chemotherapy [209]. High levels of ΔNp63α protein in HNSCC accurately predicted a more favourable response to cisplatin treatment [209]. 

Chemosensitivity to cisplatin has also been shown to be related to ΔNp63α expression in a biologically defined subset of breast tumours [210]. Triple-negative breast carcinomas exhibit co-expression of TAp73 with inhibitory ΔNp63α, which has been shown to be important in their enhanced chemosensitivity to cisplatin. Following cisplatin treatment, TAp73 undergoes phosphorylation of TAp73, which promotes dissociation of the TAp73/ΔNp63α complex, thus enabling activation of p73-dependent apoptosis [210]. This may define response to chemotherapy for other tumours that co–express TAp73 and ΔNp63α. 

Conversely, in another study, levels of TAp63 and ΔNp63 were compared across different stages of ovarian carcinoma [211]. This showed that high ΔNp63 expression correlated with a poor response to platinum-based therapy [211]. 

Put together, these data do support a role for ΔNp63α in mediating the response to cisplatin. However, its significance in chemosensitivity to other chemotherapeutic agents in different tumour types is yet to be evaluated.
  
1.5.4.1.3 Molecular mechanisms implicated in tumourigenesis
The role of ΔNp63 in cancer pathogenesis, through regulation of cellular proliferation and the cell cycle, has been explored. It was initially hypothesised that over-expression of ΔNp63 might simply be a mechanism to inactivate p53. However, its effects in tumourigenesis are now believed not to be exclusively through antagonising p53, but by conferring a proliferative effect on cancer cells through the transactivation of target genes indispensable for cell division. For example, p63 inhibition has been shown to induce apoptosis by upregulating pro-apoptotic Bcl–2 family genes Puma and Noxa, through a mechanism independent of p53 status of the cells [189].  More recently, it was reported that ΔNp63 overexpression is associated with downregulation of the cyclin-dependent kinase inhibitors (CKIs) p27 and p57 [212]. The effects on cell growth were associated with increased G1 phase cell and apoptotic population. Therefore, it would seem that ΔNp63 acts to promote tumour cell proliferation by directly affecting transcription of a number of target genes, including some that are not implicated in p53 pathways, but the extent of these is still unfolding. 

The precise molecular pathways mediating p63 function in tumourigenesis remains unclear. However, it has previously been reported that ΔNp63α inhibits phosphorylation of β–catenin, and therefore induces nuclear accumulation of β–catenin and signalling [160], [191]. This represents an important pathway that mediates the oncogenic role of ΔNp63α. 

More recently, it was reported that p63 may promote cell survival through fatty acid synthase (FASN) [213]. FASN is a key enzyme involved in the biogenesis of membrane lipids in rapidly proliferating cells and FASN has been shown to be a direct transcriptional target of ΔNp63α [214]. Sabbisetti et al have shown that FASN activity is regulated by p63, thereby establishing a functional link between p63 and cellular metabolism [213]. Furthermore, they also evaluated the role of p63 in modulating PI3K/Akt signalling, as this pathway has been extensively implicated in cell survival. They observed that p63 silencing resulted in reduced phosphorylation of Akt, thereby suggesting that p63 modulates Akt activation. This has also been supported by Ogawa et al, who reported that activation of the Akt pathway is necessary for ΔNp63α protection against UV-induced apoptosis [215]. Interestingly, preliminary results from our own group imply that Akt regulates phosphorylation of p63 (data not published), and may therefore be implicated in post-translational modifications of p63. This would suggest that Akt might function both upstream and downstream of p63. 

1.5.4.2 ΔNp63α expression in head and neck cancer
It is widely reported that HNSCC maintain expression of high levels of ΔNp63α  [173], [216]. In addition, it has been proposed that aberrant p63 expression maybe an early event in the pathogenesis of HNSCC, as extension of p63 expression is observed from normal basal cells into suprabasal levels in specimens displaying dysplasia [217].  

The importance of p63 expression in head and neck cancers has been evaluated for its clinicopathological significance. Lo Muzio et al reported that high p63 expression is associated with a more aggressive phenotype and poor prognosis [218]. However conversely, Oliveria et al found the reverse [219]. Interestingly, they evaluated both the quantity of cells stained for p63 as well as the intensity and in doing so, found that a higher disease-free survival and overall survival correlated with a both a high index of p63 staining, as well as stronger intensity pattern. This variability in immunohistochemical evaluation may be due to a failure to distinguish between the p63 isoforms detected. The 4A4 antibody is most commonly employed for immunohistochemical analysis, but our own data has confirmed that this is not specific for any p63 isoforms. Therefore, the differences may be due to detection of differential isoforms.  

1.5.4.3 ΔNp63 expression in pancreatic cancer
The experience of p63 expression in the pancreas is limited. It is reported that ∆Np63 is not expressed in normal pancreas and that it is also absent in pancreatic intraepithelial neoplasia (PanIN) of various grades [184]. However, it is strongly and uniformly expressed in the foci of squamous/transitional metaplasia. Transitional/squamous metaplasia typically manifests as multi-layered epithelium with some degrees of disorganisation and may therefore mimic high-grade PanINs. As high-grade PanINs may have the potential for progressing to invasive carcinoma, the distinction of PanINs from squamous metaplasia is clearly important. The differential expression of ∆Np63 may therefore be of diagnostic value.  

With regards to invasive carcinomas, expression of p63 has been reported to vary widely from 4% to 68.2% of ductal adenocarcinomas of the pancreas [184], [220], [183]. As in other organs including the lung and oesophagus [178], [174], [161], [221], [222], p63 is also reported to be a reliable marker of squamous differentiation in pancreatic carcinoma. Basturk et al confirmed ∆Np63 immunoexpression to be limited only to the areas of squamous differentiation [184]. Ordinary ductal adenocarcinomas, including poorly differentiated components were negative for this marker. This differentiation may be important in determining the primary source of metastatic carcinomas both in the liver and pancreas itself, as pancreatic carcinomas are one of the commonest tumours to metastasise to the liver. Furthermore, lung cancer is the most common tumour to metastasise to the pancreas [223]. Therefore, p63 may be useful in this distinction. 

There is no clear indication of the value of p63 as a potential biomarker to predict prognosis. Ito et al did not identify any correlation between p63 expression and other clinicopathological features [183]. However, to our knowledge, this has not yet been further evaluated in the literature. Overall, there is very limited information and great discrepancies in the reports of the expression of p63 in pancreatic cancer. The precise p63 isofom or splice variant that is implicated is also not clear. Therefore, it is vital to further define the role of p63 in the development of pancreatic cancers and re-examine its effect on prognosis and other clinicopathological features. 

1.6 Gene Expression Profiling 




1.6.1 p63 and Gene Expression Profiling
Gene expression profiling technologies are increasingly being used to understand the transcriptional complexities of cancers. More specifically, it has the potential to be used to identify transcriptional signatures, in an attempt to understand the underlying molecular mechanisms implicated in tumourigenesis. 

There is emerging literature from studies that have used gene expression profiling to identify some p63 target genes. For example, Yang et al used microarrays covering the entire human genome, to identify that p63 targets are enriched for genes involved in cell adhesion, proliferation, death, and signaling pathways [187]. Other groups have also implicated p63 to contribute most notably to cell adhesion programs, thereby regulating an effect on tumour invasion and migration[196], [224]. Boldrup et al used gene expression profiling to compare the transcriptional properties between the three ΔNp63 splice variants (α, β and γ) [225]. They used an HNSCC-derived cell line, Fadu, stably transfected with each of the three ΔNp63 isoforms, to investigate the potential for different transcriptional activation activities, and found that ΔNp63β was the most efficient inducer, and ΔNp63γ the weakest [225]. They also idenitified Cox-2 as a novel p63 target gene, which may influence both prognosis and therapeutic response [225]. Conversely, prior to this, Wu et al found that ΔNp63α was the most potent transcriptional activator of all the TA and ΔNp63 isoforms, of Hsp70 in human cancer  [202].  

Importantly, the ability of short interfering RNA (siRNA) to mediate sequence-specific gene silencing in mammalian cells [226], now provides a strategy to derive two RNA populations to compare p63-regulated genes.  


1.7 Short interfering RNA (siRNA)
RNA interference has emerged as a powerful tool for dissecting and understanding gene function. However, introduction of long double-stranded RNA (dsRNA) into mammalian cells posed an immediate obstacle. dsRNA longer than 30 nucleotides were found to activate a dsRNA-dependent protein kinase (PKR), which leads to activation of an interferon response [227].

The interferon system is an innate antiviral immune response, which can be triggered by dsRNA, most commonly in response to viral infection. This provokes synthesis and secretion of interferons (IFNs), which mediate induction of a cellular antiviral state that obstructs further viral spread. Type I IFNs (α and β) are produced by many cell types, while Type II IFN (gamma) is produced by immune cells. IFN-induced signaling pathways begin with IFN binding to IFN receptors at the cell surface. This results in signal transduction via the Jak-Stat pathway, which leads to activation of interferon-responsive genes and synthesis of effector proteins. This results in global degradation of mRNA and inhibition of mRNA translation.  The ultimate aim of this response is to prevent viral multiplication but in the process it can affect growth and cause damage to the host cell.  In the context of RNA interference, the introduction of dsRNA into mammalian cells also provides a similar stimulus for the host to raise an interferon response, in its attempt to clear the dsRNA.






Fig. 1.9: Proposed mechanism of RNA interference in mammalian cells (Adapted From [230]. Long double-stranded RNA is cleaved by the endoribonuclease Dicer, into siRNAs in an ATP-dependent reaction. siRNAs are then incorporated into the RNA-inducing silencing complex (RISC). The siRNA duplex is unwound in an ATP-dependent manner.  The single-stranded antisense strand guides RISC to messenger RNA that has a complementary sequence, resulting in the endonucleolytic cleavage of the target mRNA.

Exogenous siRNAs are specifically designed for highly specific gene silencing. They are thought to require near 100% identity with the targeted transcript to cause mRNA degradation. Therefore, the high sequence specificity of RNA interference may make it suitable to treat diseases that are linked to selective or elevated expression of particular identified genes. However, the major challenge in turning RNA interference into an effective therapeutic strategy has been with the delivery of RNA interference agents, largely due to insufficient bioavailability of the compounds [231]. Therefore, the use of siRNA has so far been exploited largely as a research tool for analysis of gene function. However, this application in itself, holds great promise for research and gene therapy [232]. For instance, it has been used as a new approach to inhibit oncogenes, pro-apoptotic genes and genes encoding viral proteins [232]. Furthermore, resistance to chemotherapeutic drugs in cancer has also been addressed using RNAi. P–glycoprotein encoded by MDR1 is a multidrug transporter implicated in drug resistance. RNAi targeting MDR1 has been shown to overcome drug resistance against daunorubicin to 89% or 58% in pancreatic and gastric carcinomas respectively [233]. This highlights the potential of this approach in its application against other tumour-associated target genes. 

1.7.1 Short interfering RNA delivery
Two main methods have developed to utilise RNAi via the siRNA pathway in mammalian cells.  Firstly, siRNAs have been introduced into mammalian cells by transient transfection of synthetic double-stranded RNA [226].  The major drawback of this method is the transient nature of the silencing effect. This becomes important when trying to reduce the level of proteins with a long half-life or when an RNAi specific phenotype only appears after an extended period of time. To overcome these problems siRNA expression vectors have been developed that can be stably introduced into cells either as selectable plasmids or as viral vectors [234], [235], [236].  These vectors utilise the RNA polymerase III promoters of the H1 or U6 genes to produce a short RNA hairpin. The loop of the hairpin is then cleaved by the Dicer endonuclease in the cell, to give a functional siRNA as shown in Figure 1.10. 


Figure 1.10: shRNA processing: shRNA produced by shRNA expression vectors is cleaved by the Dicer endonuclease in the cell to give a functional siRNA.
	
1.7.2 Short Interfering RNA and Off Target Effects
Despite the reported sequence-specific nature of the siRNA mediated RNA interference, many reports have highlighted the potential for non-specific effects. A number of approaches have been suggested to minimise the occurrence of such ‘off–target’ effects. It has been suggested that using a number of different siRNA sequences targeting the same gene should provide some control for the specificity of any observed knockdown effect [237].  Also, the inclusion of non-silencing siRNAs, containing either a base-pair change from the target, or target a non-mammalian sequence, should also be used to serve as a further control for off-target effects [238].  
1.8 Aims
The primary objective of this project was to determine the clinical and biological implication of p63 expression in primary head and neck and pancreatic cancers. 




























2.1 Human cell lines 
All cell lines were maintained in their respective media at 37C in air supplemented with 5% carbon dioxide (CO2). Repeated experiments were performed using cells of similar passage. All cells were grown in media obtained from Cancer Research UK Central Cell Services (CRUK CCS), containing 0.06μg/l penicillin (Sigma-Aldrich) and 0.1μg/l streptomycin (Sigma-Aldrich) unless otherwise stated.  All cells were regularly passaged to maintain exponential growth.  Cells were fingerprinted for identity at CRUK CC by short tandem repeat profiling [239], and were regularly screened for Mycoplasma sp. contamination. 

2.1.1. Head and Neck Squamous Cell Carcinoma
The human head and neck squamous cell carcinoma (HNSCC) cell lines SCC4 (tongue) and SCC25 (tongue) were obtained from the CRUK CCS and were maintained in 1 Dulbecco’s Modified Eagle’s Medium (DMEM): 1 Ham’s F12 supplemented with 10% heat-inactivated foetal calf serum (FCS; obtained from PAA) and 400ng/ml hydrocortisone (Sigma-Aldrich). The HNSCC cell lines TR126 (tongue) and TR138 (larynx) were obtained from the CRUK CCS and were maintained in DMEM and HAM’S F12 respectively, each with 10% FCS. Fadu (pharyngeal) was obtained from American Type Culture Collection (ATCC) and maintained in Earle’s Minimal Essential Medium (EMEM) with 10% FCS.

2.1.2 Pancreatic carcinoma
The pancreatic carcinoma cell lines Suit-2, PaTu8988s, PaTu8988t, MiaPaCa2, Panc1, Capan1 and HS766T were obtained from CRUK CCS and maintained in DMEM with 10% FCS.


2.1.3 Breast carcinoma 
The mammary carcinoma cell line MCF 7 was obtained from CRUK CCS and maintained in DMEM with 10% FCS.

2.1.4 Human fibroblast




2.2.1 p63 plasmids 
The pcTAp63α, pcΔNp63α, pcΔNp63β, TAp63γ and ΔNp63γ vectors were kindly provided by Yaohe Wang (Institute of Cancer, Queen Mary University of London). p63 plasmid construction was performed by Ming Yuan (MY - Institute of Cancer, Queen Mary University of London). Briefly, the human gene sequences for each p63 isoform were cloned into the transfer vector pGEM–T (Promega). Each complete p63 cDNA was then subcloned into a pcDNA3.1 mammalian expression vector (Invitrogen Ltd). pcDNA3.1 (Invitrogen Ltd.) was used as the empty control vector. Natasha Choudhury (NC) performed miniprep plasmid purification of pcDNA 3.1 and pcΔNp63α.

2.2.2 Minipreparation of plasmid purification
2.2.2.1 Bacterial transformation of competent cells
One Shot® TOP10 chemically competent E. Coli cells (Invitrogen Ltd.) were used for bacterial transformation of pcDNA3.1 and pcΔNp63α plasmids (containing ampicillin resistant gene). One vial of S.O.C medium (Invitrogen Ltd.) was warmed to room temperature and one vial of One Shot® TOP10 cells were slowly thawed on ice. Once thawed, 25µl chemically competent cells were transferred to two separately labelled, clean microcentrifuge tubes. 1.5µl of plasmid DNA was added to its’ respective tube and mixed gently by repeated inverting, to allow the plasmids to deposit onto cells. The tubes were incubated on ice for 30 minutes, before the cells were heat shocked in a 42ºC water bath for 30 seconds. The tubes were then returned back into ice for five minutes. 475µl pre-warmed nutrient rich S.O.C medium was added to each tube before shaking horizontally at 37ºC for one hour in a shaking incubator, to allow cells to recover. Following this, 25µl transformed cells, from each transformation, were plated onto pre-warmed ampicillin-selective agar plates and incubated overnight at 37ºC. The following day, Luria-Bertani broth (LB; Sigma-Aldrich) was warmed to room temperature, ready for inoculation of transformed cell colonies. Single cell colonies from each set of clonally propagated cells was selected and inoculated into 15mls pre-warmed LB containing 100µg/ml ampicillin (Sigma-Aldrich), and incubated to allow further growth at 37ºC in a shaking incubator overnight.

2.2.2.2 Plasmid DNA Purification
The QIAprep Spin Miniprep Kit (QIAGEN Ltd.) was used to yield plasmid DNA from bacterially transformed E. Coli cells in LB medium. 2ml of LB E. Coli was collected and centrifuged at 4,000 rpm for 10 minutes. The pelleted bacterial cells were resuspended in 250µl Buffer P1 and transferred to individually labelled microcentrifuge tubes. 250µl Buffer P2 was added and mixed thoroughly by inverting five times, to lyse the cells. 350µl neutralising Buffer N3 was then added and mixed immediately and thoroughly, again by inverting five times. The solution was centrifuged at 13,000 rpm for 10 minutes, and the supernatants were applied onto the silica-coated membranes of individual QIAprep spin columns, by pipetting. These were centrifuged at 6,000 rpm for 60 seconds and the flow-through discarded. Endonucleases were washed by adding 750µl Buffer PE to the spin columns and centrifuging at 7,000 rpm for a further 60 seconds. The flow-through was discarded and the columns centrifuged at high speed for an additional one minute, at 13,000 rpm, to remove any residual wash buffer. The spin columns were then placed into clean 1.5ml microcentrifuge tubes. To elute the DNA, 50µl double-distilled water was added onto the centre of the silica membranes of the spin columns, to dissolve the plasmids for elution. They were centrifuged at 13,000 rpm for one minute, and the purified plasmid DNA concentration determined using the Nanodrop ND-Spectrophotometer and Nanodrop version 3.1.0 software (NanoDrop Technologies, Delaware, USA).  

2.2.3 Transient transfection of plasmid DNA
Cells were seeded into 6 well plates in 2ml of their respective complete media, the day before transfection, to reach 50 – 80% cell confluency at the time of transfection (Table 2.1). Effectene® transfection reagents (QIAGEN Ltd.) were used for transfection. For each well, 0.4µg plasmid DNA was diluted in Buffer EC, to a total volume of 100µl, and 3.2µl Enhancer added before mixing by vortexing for one second. The mixture was incubated at room temperature for five minutes, and then 10µl Effectene® reagent added to the DNA – Enhancer solution. This was mixed by vortexing for a further 10 seconds and incubated at room temperature for 10 minutes, to allow transfection – complex formation. 600µl complete growth media was added to the transfection complex and mixed by pipetting up and down. This was added dropwise onto the cells that had already been replenished with 1.4mls fresh growth medium. Cells were incubated at 37ºC and 5% CO2 for 24 to 48 hours to allow expression of the transfected gene.

Table 2.1: Cell seeding for plasmid DNA transfection: numbers of cells seeded per well, into a 6 well plate, to achieve 50 – 80% confluency for plasmid DNA transfection.













2.3.1 p63 silencing oligonucleotides
2.3.1.1 p63 shRNA
Four pre-designed TP63 human shRNA contructs (OrigeneTM) were obtained (Table 2.2) and their gene silencing efficiency already validated by MY. 


Table 2.2: p63 shRNA target sequences.








Of these, the most efficient TP63 shRNA expression cassette, T1334747, was cloned into the retroviral vector pRS (OrigeneTM) by MY, which can be used for both transient and stable transfection. A pRS vector carrying a 29-mer scrambled sequence cassette was used as negative control (Origene TM).

2.3.1.2 siRNA 
A pool of four synthetic TP63 siRNAs, based on highly conserved p63 sequence (SMARTpool; Dharmacon Research) was used for RNA interference. This Custom SMARTTM pool reagent was used to knock down endogenous p63 expression. 

Custom SMARTTM pool siRNA reagents for PRSS23 and BMP2K were also used to knock down endogenous PRSS23 and BMP2K respectively (Dharmacon Research). Each of these SMARTpools was also composed of four synthetic siRNAs based on their respective gene sequences.

A non-specific random control sequence, RISC free negative control (Dharmacon Research) was used for a non-silencing control. These siRNA target sequences are detailed in Table 2.3.  


Table 2.3: siRNA target sequences: TP63, PRSS23, BMP2K and RISC free® negative control siRNA target sequences. The non-specific random sequence was used for a non-silencing control for transient transfection.  


















2.3.2 Transfection with silencing oligonucleotides 
2.3.2.1 Stable transfection of p63 shRNA
2.3.2.1.1 Puromycin titration
Stably transfected cell clones were selected with puromycin (Sigma-Aldrich). First the optimum concentration of puromycin required was determined by titration. MiaPaca 2 cells were seeded at a concentration of 2.5 x 10 5 cells / well in 2mls of complete growth medium, into a 6 well plate. The following day, the cells were replenished with serial dilutions of puromycin containing culture medium (0.25μg/ml, 0.5μg/ml, 0.75μg/ml, 1.0μg/ml, 1.25μg/ml and 1.5μg/ml). The lowest concentration of drug that resulted in massive cell killing by three days and killed all cells by two weeks was used for antibiotic selection of stable cell lines.

2.3.2.1.2 Stable transfection and drug selection
MiaPaca 2 cells were seeded into each well of a 6 well plate in 2ml of their respective antibiotic free media with 5% FCS, to reach 50 - 80% confluency the following day (Table 2.1). On the day of transfection, cells were transiently transfected with pRS, pRS TP63shRNA and mock transfections, with no DNA, using Effectene® transfection reagent (section 2.2.3). Following 48 hours, cells were split 1:10 into two 10cm plates containing 12ml complete growth medium. Cell growth was monitored daily and the media changed every two to three days to select for stably transfected cells, by continuous growth in 0.5μg/ml puromycin-containing selective medium. This was continued for two to three weeks, with frequent changes of medium to eliminate dead cells and debris, until distinct colonies were visualised. Once all mock-transfected cells had died, single cell clones from each plate of cells transfected with empty vector and pRS TP63shRNA were harvested and transferred to fresh 6 well plates for further propagation in the presence of selective medium. Samples of cell suspensions from each of the surviving groups of selected cell clones were used to screen for any gene silencing in the stable transfectants, using Western blot (section 2.4).

2.3.3. Transient transfection with siRNA oligonucleotides




Table 2.4: siRNA resuspension volumes and concentrations; as recommended by Dharmacon Research.
















Table 2.5: Cell seeding for siRNA transfection: numbers of cells seeded per well, in a 6 well plate, to achieve 30 – 50% confluency for siRNA transfection. 












2.4 Western Blot 
2.4.1 Sample preparation 
Lysates from cell samples to be screened with western blot analysis were prepared. Cells from each sample were detached with warm trypsin (Sigma-Aldrich) and neutralised in complete growth medium. Individual cell suspensions were collected into labelled Falcon tubes and centrifuged at 5,000 rpm for four minutes. Supernatants were aspirated and cell pellets were washed in 1ml of PBS at 4ºC and centrifuged at 2000rpm for five minutes at 4ºC. Following removal of PBS, cells were resuspended in 150μl of NP40 cell lysis buffer (50mM Tris pH7.4, 150mM NaCl, 10mM Ca2+, one protease inhibitor cocktail tablet (Roche Applied Science) and 1% Nonidet P40 (Sigma-Aldrich) prior to storage at -80C. 

2.4.2 Beckman protein assay
Protein concentrations of cell samples were determined using the Beckman protein assay. 5μl of protein lysate samples were mixed with 200μl Bio-Rad protein assay indicator (Bio-Rad) and 795μl of distilled water in cuvettes (Fisher Scientific). Following calibration with a blank sample (200μl Bio-Rad indicator and 800μl distilled water), the absorbance at 595nm was measured for each sample, using a spectrophotometer (Beckman Coulter UK Ltd.). The protein concentration of samples was determined from a standard curve of protein concentration against absorbance of known quantities (1, 2, 4, 8, 16, 32 and 64μg) of bovine serum albumin (BSA; Sigma-Aldrich) at 595nm. 

2.4.3 SDS-Polyacrylamide gel electrophoresis
20μg of samples were mixed with 3μl of 4x loading buffer (50mM Tris, 4% SDS, 10% Glycerol, 5% Mercaptoethanol and 0.01% Bromophenol Blue) and distilled water to give a final volume of 12μl. Samples were heated to 100C for five minutes and cooled on ice for one minute prior to loading. 

10% running gel and 4% stacking gel were prepared. Samples were loaded into lanes of the gel, covered with 1X Tris Glycine SDS Electrophoresis running buffer (Fisher Scientific). 10μl of Rainbow molecular weight marker (Amersham Biosciences) was loaded alongside the protein samples to allow size determination of detected proteins. Electrophoresis took place at 150V for 60 - 70 minutes. Separated proteins were transferred onto a nitrocellulose membrane (Amersham Biosciences) using a semi-dry blotting method.  Proteins were sandwiched between blotting paper in the presence of transfer buffer (1% glycine and 10% methanol in distilled water) and transferred onto nitrocellulose membranes (Amersham Biosciences) using a semi-dry transfer system (Trans-Blot, Bio-Rad, CA, USA) at 20V for 40 minutes, 

Membranes were blocked with a 5% solution of non-fat milk protein Marvel (Nisa) in a solution of 1% Tween®20 (Sigma-Aldrich) in PBS for one hour at room temperature. The primary antibodies (Table 2.6) were diluted in blocking solution and incubated with the membrane at 4ºC overnight or at 37ºC for one hour. Following removal of the primary antibody, membranes were washed three times for 10 minutes with 1x TBS-T washing buffer (Tris-Buffered Saline from National Diagnostics, 0.5% Tween®20), to remove excess antibody. Secondary horseradish peroxidase (HRP)-conjugated antibodies were diluted in blocking solution and incubated with membranes for 45 minutes at room temperature. Three further 15-minute washes with 1x TBS-T each time, were performed following removal of the secondary antibody.
Chemiluminescent detection was performed using ECL Plus Detection reagent (GE Healthcare) according to the manufacturer’s instructions. The signals were visualised by exposing membranes to BioMaxMR film (Kodak) for 1-10 minutes.

Membranes were washed once again in 1x TBS-T prior to incubation with PCNA or -actin primary antibody, as loading controls using the same protocol.
Table 2.6: Primary and secondary antibodies used for Western blotting. 
Antibody	1º/ 2º	Species	Dilution	Supplier
4A4	1º	Mouse monoclonal	1:250	Santa Cruz Biotechnology
p63α	1º	Rabbit polyclonal	1:250	Santa Cruz Biotechnology
p40 (ΔNp63)	1º	Rabbit polyclonal	1:500	Calbiochem
PARP	1º	Rabbit polyclonal	1:1000	Cell Signalling Technology
Cleaved PARP	1º	Rabbit polyclonal 	1:1000	Cell Signalling Technology 
Caspase 3	1º	Rabbit polyclonal	1:1000	Cell Signalling Technology
Cleaved Caspase 3	1º	Rabbit polyclonal	1:1000	Cell Signalling Technology
Bcl - 2	1º	Mouse monoclonal	1:250	Santa Cruz Biotechnology
BMP2K	1º	Mouse monoclonal	1:250	Abcam
PCNA	1º	Mouse monoclonal	1:1000	Santa Cruz Biotechnology




2.5 Soft agar colony formation assay  
The oncological transformation potential of transfected cells was tested using soft agar colony formation assay, as an indicator of tumourigenicity in vitro. The number and size of colonies formed in cells transfected with TP63 siRNA were compared to control siRNA-transfected cells. 

2.5.1 Sample preparation 
Cells for p63 knockdown experiments were seeded into each well of a 6 well plate (Table 2.5). For each cell line, three wells were transfected with Custom SMARTTM pool TP63 siRNA and three wells with RISC free negative control siRNA (section 2.3.3). Cells for p63 overexpression experiments were also seeded in a 6 well plate (Table 2.1) and transiently transfected in the same manner with pcDNA 3.1 and pcΔNp63α (section 2.2.3). 24 hours following transfection, cells were harvested for soft agar colony assay.

2.5.2 Soft agar assay
Soft agar plates were prepared. 1% low melting temperature (Tm) agarose (Tm<65ºC; FMC BioProducts) was melted in a microwave and cooled in a 42ºC water bath. 2X medium supplemented with 20% FCS was warmed to the same temperature, and then equal volumes of the two solutions were mixed to make 0.5% Agar + 1X media + additives base agar solution. 2ml of base agar solution was added into each well of a 6 well plate, and left to cool and solidify for 30 minutes at room temperature. The top agar solution was then prepared. 0.7% agarose was melted and cooled to 42ºC. Equal volumes of this were mixed with warmed 2X media supplemented with 20% FCS. Control cells and p63 siRNA or pcΔNp63α transfected cells were then seeded onto the base layer, in triplicate. 50,000 cells were resuspended in 1.5ml top agar solution, and added onto the base layer.  This was left to cool and solidify for a further 30 minutes, at room temperature. Once set, 2ml of normal complete media supplemented with 10% FCS was added over the top agar layer. Plates were incubated at 37ºC with 5% CO2 and re-fed with fresh normal complete media twice weekly, for three to four weeks or until colonies were apparent. Prior to colony counting, 1ml MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Promega) was added to each well for one hour, to stain viable colonies. The total number of colonies that appeared subjectively larger than the average sized colonies in the control plates were counted.


2.6. Cell growth assay
2.6.1 Cell preparation 
Cells for knockdown experiments were seeded the day before transfection (Table 2.5) and then transfected with TP63, PRSS23 or BMP2K Custom SMARTTM pool siRNAs and RISC free negative control siRNA, using three wells of each in a 6 well plate (section 2.3.3).  Cells for p63 overexpression experiments were transfected with pcDNA3.1 and pcΔNp63α, with three wells of each, as described in section 2.2.3. Following 24 hours transfection, cells were harvested for cell growth assays.

2.6.2 Cell growth assay










Table 2.7: Cell seeding for cell growth assay: number of cells seeded per well in a 24 well plate.













2.7 Cell migration assay
2.7.1 Cell preparation  
Cells for knockdown experiments were seeded for transfection (Table 2.5). Cells were transfected with TP63, PRSS23 or BMP2K Custom SMARTTM pool siRNAs and RISC free negative control siRNA, with three wells of each in a 6 well plate, as described in section 2.3.3.  Cells for p63 overexpression experiments were seeded (Table 2.1) and transfected with pcDNA 3.1 and pcΔNp63α, also with three wells of each, as described in section 2.2.3. 24 hours after transfection, cells were harvested for cell migration assays.

2.7.2 Transwell migration assay
The effect of ΔNp63α expression on tumour cell migration was observed using transwell migration assays. Following 24 hours transfection, cells were harvested and re-seeded into transwell migration assay chambers containing   8μm porous polyethylene tetraphthallate (PET) membrane (BD BiocoatTM science). 50,000 cells were suspended in 500μl of serum-free medium and plated into the upper chambers, in triplicate. 750μl growth medium supplemented with 10% FCS was added to the lower chamber, to serve as a chemoattractant. Plates were incubated at 37ºC in air supplemented with 5% CO2 for 24 hours. Following this, cells which had migrated through the porous membrane were counted. Medium from the upper and lower chambers was aspirated and 500μl warmed trypsin warmed to 37ºC was added to the lower chamber and migration assay plates were  incubated at 37ºC  in air supplemented with 5% CO2 for one hour. Cells from the undersurface of the membrane and those that had migrated through into the lower chamber were counted using a Casy® cell counter (Sharfe System GmbH, Germany). Experiments for each cell line were repeated at least three times.


2.8 Cell invasion assay
The invasive potential of cells was measured using BD BiocoatTM MatrigelTM (BD Bioscience) invasion chambers.

2.8.1 Cell preparation for transwell invasion assay 
Cells were seeded for p63 knockdown overnight (Table 2.5) and then transiently transfected with Custom SMARTTM pool TP63 siRNA and RISC free negative control siRNA, with three wells of each in a 6 well plate, as described in section 2.3.3.  24 hours after transfection, cells were harvested for cell invasion assays.

2.8.2 Transwell invasion assay




Epithelial cells are grown at an air/liquid interface on collagen matrices populated with fibroblasts. This model allows the study of cell interactions, between tumour cells and stromal fibroblasts. Organotypic cultures were used to compare cells transfected with TP63 siRNA and RISC free negative control siRNA, to confirm the effect of ΔNp63α on tumour cell invasion, in a 3-dimensional model. 

2.9.1 Gel preparation







Table 2.8: Volume ratios for composition of organotypic gel; 1ml of total composition required for each gel; a small extra volume is made to allow for some lost volume when making the gel.

Component	Initial concentration	Volume (μl)






Concurrently, a fibroblast-free free collagen gel mix was made up and used to coat nylon discs, which were previously autoclaved (Tetko Inc, New York, USA). After 24 hours, polymerisation at 37ºC for 10 minutes, the coated nylon discs / gels were fixed in 1% glutaraldehyde (Sigma - Aldrich) diluted in PBS for one hour. They were then washed four times in PBS and twice in alpha MEM supplemented in 10% FCS and glutamine (Sigma-Aldrich). They were then kept at 4ºC until required.  After 24 hours, the medium was carefully aspirated from over the gels and 5x106 transfected cells suspended in media supplemented with 10% FCS was added over the gel, in duplicate. The gels were then incubated at 37ºC for 24 hours. 

2.9.2 Assembly of organotypic culture
The following day, sterile steel grids composed of 2.5cm2 squares of stainless steel mesh with edges bent down to form 5mm ‘high legs’, were placed in 6 well plates. The gel-coated nylon meshes were placed onto the sterile grids. The organotypic gels were prepared for assembly. The medium was aspirated from over the gels in 24 well plates and each gel was carefully removed from the 24 well plate using a sterile spatula, and placed onto individual gel coated nylon discs, resting on steel grids (Fig. 2.1). Growth medium was added into each well, sufficient to reach the undersurface of the grids. The medium was replenished every two to three days. The gels were harvested after six days for processing.


Fig 2.1: Assembly of organotypic culture.

2.9.3 Gel processing 
Following the incubation period, each organotypic gel was processed for analysis. The gels were cut in half using a disposable blade and immersed in formal saline overnight. The following day, they were placed into 70% ethanol for fixation, before processed for hematoxylin and eosin (H&E) staining.





The cell killing potency of cell lines expressing endogenous p63, PRSS23 or BMP2K compared with knockdown cell lines was determined by CellTiter 96® AQueous Non-Radioactive Cell Proliferation assay. The MTS (3 - (4,5 -dimethylthiazol - 2 - yl) - 5 - (3 - carboxymethoxyphenyl) – 2 - (4 - sulphophenyl) - 2H - tetrazolium; Promega) cell proliferation assay was used to determine the dose required of chemotherapy drug required to kill 50% of cells in a culture system. The proportion of cells alive after three days at each drug concentration for p63 knockdown cells compared to control siRNA transfected cells was determined following the addition of MTS reagents. The assay measured cell survival by dehydrogenase enzyme activity found in metabolically active cells, which reduced MTS into formazan in proportion to the number of living cells present. 

2.10.1 Cell preparation for MTS assay
Cells were initially transfected with TP63, PRSS23 or BMP2K Custom SMARTTM pool siRNAs and RISC free negative control siRNA in 6 well plates (section 2.3.3). Following 48 hours transfection, cells were harvested and re-seeded into 96 well plates. Cells were cultured in 90l of medium with 10% FCS in 96 well plates at a density of between 2000 and 5000 cells per well, depending on the rate of cell growth, to ensure that control wells were nearly confluent three days after drug treatment (Table 2.9). Row 1 was filled with 100l complete medium without any cells. The outer rows 1 and 8, and the last column 12 were filled with PBS.


Table 2.9: Cell seeding for MTS assay: number of cells seeded in 90l per well, in a 96 well plate.










Following overnight incubation, cells were treated with chemotherapy drugs. Gemcitabine (Barts Hospital pharmacy), 5-Fluorouracil (5FU; ONCO TAIN®) or cisplatin (ONCO TAIN®) was added to each well in a volume of 10l starting with the stock concentration of each drug (Table 2.10). This was serially diluted in complete medium, 1 in 10, in sextuplet, across the plate. For each row, there were 10l of nine serial dilutions of drug. Each 96 well plate was set up as shown in Fig. 2.2.


                        
                Stock












Fig. 2.2: 96 well plate set up for MTS assay; Column 1 indicates 100l complete medium. 100l PBS was added to the wells indicated. The central 60 wells were seeded with 90l  transfected cells, which were treated with 10l chemotherapy drugs, serially diluted 1 in 10. Arrow indicates sextuplet treatment for each drug concentration.


Table 2.10: Drugs used in chemosensitivity experiments; stock concentration used for maximal dose and serially diluted 1 in 10, to treat cells. Final concentration is 10l of stock diluted in 90l of complete medium.






Three days following treatment, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium; Promega) was added to PMS (phenazine methosulfate; Sigma-Aldrich) according to the manufacturer’s instructions in a ratio of 20MTS: 1PMS. 20l was added to each well and plates incubated for one to three hours. Cell viability was determined by measuring the absorbance or optical density (OD) at 490nm using an Opsys MR 96 well plate absorbance reader (Dynex, VA, USA). Cell viability was determined in p63 or control siRNA transfected cells treated with conventional chemotherapy agents, after correction for absorbance due to the media alone (negative control). The concentration of drugs required to kill 50% of cells (Half maximal effective concentration or EC50) was then calculated for each cell line (Section 2.13.1) and a dose-response curve created by non-linear regression using Prism® (GraphPad Software, CA, USA). The EC50 values were taken as the optimal dose of virus to use in subsequent experiments. All experiments were repeated in triplicate and on three separate occasions. 

Similar MTS assays were done to determine the chemosensitivity of parental cell lines. Untransfected parental cells were seeded into 96 well plates (Table 2.9) and treated with chemotherapy drugs, serially diluted, as illustrated in Fig. 2.2. MTS assay was performed three days following drug treatment, as described above.
 

2.11 Gene Expression Microarrays
2.11.1. The Affymetrix GeneChip




MiaPaca 2 cells were seeded and transfected with TP63 siRNA and control siRNA, using three wells for each, in a 6 well plate (Table 2.5, section 2.3.3). This was repeated on three separate occasions, with cells less than P5. 48 hours following transfection, one well of treated and control cells was harvested to collect cell lysates for Western blot (section 2.4), from each experiment, in order to determine efficiency of p63 knockdown. The remaining two wells of control cells and two wells of TP63 siRNA-transfected cells from each experiment were used to obtain pellets for purification of total RNA. Pellets were collected by centrifuging for five minutes at 4000 g.   


2.11.2.2 Total RNA purification 
The purification of total RNA was done using the RNeasy Mini Kit (Spin columns and reagents; QIAGEN Ltd.) according to the manufacturers’ instructions. Cell pellets from triplicate experiment samples were lysed and homogenised to inactivate RNases to ensure purification of intact RNA. Samples were then applied to RNeasy Mini spin columns, where total RNA bound to a silica-based membrane, while contaminants were washed away before the elution of purified RNA.

Cell pellets were disrupted by adding 350μl buffer RLT and mixed by pipetting. Lysates were homogenised by passing through a blunt 20-gauge needle fitted to an RNase-free syringe five times. Lysates were transferred to spin columns containing a silica-based membrane, placed in 2ml collection tubes, and centrifuged at 8000g for two minutes. 350μl 70% ethanol was added to the homogenised lysates and mixed by pipetting. 700μl of the samples were transferred into fresh spin columns and placed in new 2ml collection tubes. Samples were centrifuged for 15 seconds at 8000 g and filtrates discarded. Columns were washed in the same manner with 700μl wash buffer RW1. 500μl wash buffer RPE was then added to spin columns, which were centrifuged also as above. A final 500μl buffer RPE was added and centrifuged for two minutes at 8000 g and the collection tubes discarded. Columns were placed in fresh collection tubes, samples eluted from membranes with 50μl of RNase free water, which was centrifuged at 8000g for one minute. The concentration of extracted RNA was measured, and stored at -80ºC.

Sample RNA concentration was measured using the Nanodrop ND-Spectrophotometer and Nanodrop v3.1.0 software (NanoDrop Technologies, Delaware, USA). Sample purity was determined by electropheresis using a 2100 Bioanalyser (Agilent Technology) by Vipul Bhakta (VB).

2.11.3 Microarray Expression analysis




Figure 2.3: Affymetrix GeneChip Sample and Array Processing. 


2.11.3.1 Reverse transcription: First strand cDNA synthesis
500ng of total RNA from each sample of triplicate experiments was diluted in nuclease free water to a total volume of 5μl.  This was used for reverse transcription to generate first-strand cDNA using a T7-linked oligo(dT) primer. First Strand Master Mix was prepared on ice in a nuclease-free tube, as outlined in Table 2.11. 

Table 2.11: cDNA First strand Master Mix for single reaction.

COMPONENT	Volume (μl)
1st strand Buffer Mix	4 




5μl First Strand Master Mix was added to 500ng total RNA for each sample for a final volume of 10μl. After mixing thoroughly by vortexing and a brief centrifuge, samples were incubated for two hours at 42ºC in a thermal cycler. After incubation, samples were briefly centrifuged for five seconds and kept on ice.

2.11.3.2 Second strand cDNA synthesis.
Second Strand Master Mix was prepared on ice, in a nuclease-free tube. Components were prepared as outlined in Table 2.12, for each sample reaction. After mixing gently by vortexing, the master mix was centrifuged briefly for five seconds. 20μl Second Strand Master Mix was transferred to each 10μl cDNA sample, and mixed thoroughly by vortexing and again briefly centrifuged. Each reaction was placed in a pre-cooled thermal cycler block at 16ºC and incubated for one hour, followed by 10 minutes at 65ºC. After incubation, samples were centrifuged for five seconds to collect the double-stranded cDNA, and kept on ice.


Table 2.12: Second strand Master Mix for single reaction.

COMPONENT	Volume (μl)
Nuclease free H2O	13 
2nd strand Buffer Mix	5 
2nd strand Enzyme mix	2 
Total Volume	20 
2.11.3.3 In vitro transcription to synthesis labelled aRNA
Following second-strand cDNA synthesis, in vitro transcription (IVT) was performed with biotinylated UTP and CTP, resulting in approximately 100-fold amplification of labelled RNA (aRNA). The IVT Master Mix was prepared in a nuclease-free tube, at room temperature, as outlined in Table 2.13.

Table 2.13: IVT Master Mix for single reaction.

COMPONENT	Volume (μl)
IVT Biotin Label	4 
IVT Labelling Buffer 	20 




The Master Mix was mixed by gentle vortexing and briefly centrifuged for five seconds and placed on ice. 30μl IVT Master Mix was transferred to each 30μl double stranded cDNA sample, and mixed thoroughly by vortexing, followed by a brief centrifuge to collect the reactions at the bottom of the tubes. Each reaction was placed in a thermal cycler for four hours at 40ºC. Following incubation, the aRNA samples were stored at -20ºC overnight. 

2.11.3.4 aRNA Purification





Table 2.14: aRNA Binding Mix for single reaction

COMPONENT	Volume (μl)
RNA Binding Bead	10 




60μl aRNA Binding Mix was added to each 60μl aRNA sample, and the total volume transferred to a well of U bottom Plate, and mixed by pipetting several times. For aRNA binding, 120μl 100% ethanol was added to each sample, and mixed again by pipetting. Samples were gently shaken for two minutes on the Lab-Line Titer Plate Shaker (Thermo Scientific) at setting 4, enabling aRNA to bind the RNA-binding beads. The RNA-Binding Beads were then captured by moving the plate onto a magnetic stand for five minutes. This capture was complete when the mixture became transparent and the RNA-Binding Beads form pellets against the magnets. The supernatant was then carefully aspirated and discarded without disturbing the magnetic beads. The plate was removed from the magnetic stand and the beads were washed. 100μl aRNA Wash Solution was added to each sample and samples shaken at moderate speed for one minute on the Lab-Line Titer Plate Shaker at setting 7. The plate was then moved back onto the magnetic stand and the RNA-Binding Beads captured in the same manner, described above. The supernatant was again carefully aspirated and discarded, and the plate then removed from the magnetic stand. The beads were washed for a second time with 100μl aRNA Wash Solution, as described above. Following repeat capture of the RNA-Binding Beads and discarding the supernatant, the plate was moved to a shaker for vigorous shaking for one minute to evaporate any residual ethanol from the beads, at setting 10 on Lab-line Titer Plate Shaker. The purified aRNA was then eluted from the RNA-Binding Beads by adding 50μl pre-heated aRNA elution solution to each sample. The plate was vigorously shaken for three minutes (setting 10 on Lab-line Titer Plate Shaker), or until the beads were fully dispersed. The plate was moved to the magnetic stand to capture the RNA-Binding Beads. The supernatant, containing the eluted aRNA was transferred to nuclease-free tubes, for each sample. Purified aRNA was kept on ice and RNA concentration and purity was determined using the Nanodrop ND-Spectrophotometer and Nanodrop version 3.1.0 software. RNA was accepted as adequately pure where the ratio of absorbance at 260 and 280nm was between 1.8 and 2.1.

2.11.3.5 Fragmentation of labelled aRNA
Purified labeled aRNA was fragmented before hybridization onto Genechip probe arrays, in order to obtain optimal assay sensitivity. aRNA Fragmentation mixture was prepared, as outlined in Table 2.15 (for 49/64 Array Format).

Table 2.15: aRNA Fragmentation Mixture.

COMPONENT	Volume (μl)
aRNA 	1 to 32 (15 μg)





The fragmentation reaction was incubated at 94ºC for 35 minutes. The reaction was placed on ice immediately after the incubation. 

2.11.3.6 Hybridisation




Table 2.16: Hybridisation Cocktail for single probe array.

COMPONENT	Volume (μl)
Fragmented and labelled aRNA 	33.3 (12.5 μg)








While equilibrating the probe array to room temperature, the hybridisation cocktail was heated to 99ºC for five minutes in a heat block. In this time, the GeneChip® Probe Array was wetted by filling one of the septa on the array with 200µl Pre-Hybridisation Mix. The Probe Array was then incubated at 45ºC for 10 minutes. The hybridisation cocktail already heated at 99ºC was transferred to a 45ºC heat block for five minutes, before spinning the hybridisation cocktail at maximum speed in a microcentrifuge for five minutes to collect any insoluble material from the hybridisation mixture. The heated array was then vented with a clean pipette tip to extract the Pre-Hybridisation Mix from the array with a micropipettor. It was then refilled with 200µl clarified hybridisation cocktail. The probe array was then incubated for hybridisation in the hybridisation oven at 45ºC, rotating at 60 rpm, for 16 hours.

2.11.3.7 Target hybridisation and final processing





Data analysis was kindly performed by Dr Claude Chelala (Lecturer in Cancer Bioinformatics, Institute of Cancer, Queen Mary University of London) using BioConductor packages (http://www.bioconductor.org/ (​http:​/​​/​www.bioconductor.org​/​​)), with open source R statistical environment (www.r-project.org). 


2.12 Microarray validation using qRT PCR
2.12.1 Sample preparation and total RNA purification 
MiaPaca 2 cells were transiently transfected with Custom SMARTTM pool TP63 siRNA and siCONTROLTM Non-Targeting siRNA pool three wells of a 6 well plate respectively (section 2.3.3). Transfected cells were harvested at 48 hours to obtain pellets for purification of total RNA. Pellets were collected by centrifuging for five minutes at 4000g. The purification of total RNA was done using the RNeasy Mini Kit (Spin columns and reagents; QIAGEN Ltd.) according to the manufacturers’ instructions and sample RNA concentration and purity determined (section 2.11.2.2). 
 
2.12.2 Reverse transcription reaction




Table 2.17: Reaction mixture for Reverse Transcription.

COMPONENT	Volume (μl)	Final Value





Multiscribe Reverse Transcriptase (50U/μL)	2.5	1.25 U/μL




2.12.3 Primers for selected p63 target genes























Table 2.18: Primer sequences for seven selected p63 target genes; S = sense; AS = antisense.

Gene	Primer Sequence
OGFR1	S 5’- CAGCATCTGAATGAGTCCCAGAS 5’- CTCCACAAGAGCTTCATGAAGAATA
ABI2	S 5’- CTTACAGCAGCAGTGGGAGTAGTGAS 5’- GGAGTATGGCGAGAGGCAG
MAPK1	S 5’- TTTCGTTGGCAGATGCACTAC AS 5’- CACAGTGGAGGGTGTTGCA
BMPK2	S 5’- ATCTGGGCACTGGGATGTCT AS 5’- GTCTATGTTCCGGATCTGGTTCA
DAPK3	S 5’- TTGTGGCCCCAGAGATTGTAS 5’- TCGCTGGTGTTGCTGAAGTA
PRSS23	S 5’- CGGAACAGTGCTCGGCATAS 5’- CTGGGGTCCACATGAAGAAG
SKP2	 S 5’- CCCACGATCATTTATGGACCAAS 5’- AGAGTATTGACAATGGGATCCGA




The SYBR® Green (Applied Biosystems) PCR system was used to perform qRT PCR for validation of differential gene expression of seven p63 target genes. Samples and no-template controls (nuclease-free water) were tested in triplicate. A 20μl reaction volume for each replicate was prepared. 2μl template containing 40ng cDNA from control or p63 siRNA samples was combined with 2X SYBR® Green PCR master mix buffer, forward and reverse primers and nuclease-free water (Table 2.19). Reactions were performed in MicroAmp optical 96-well reaction plates sealed with optical adhesive covers and amplified using the 7500 Real-time PCR System software. This was set up as shown in Fig. 2.4;

Step 1:	50ºC	2 mins
Step 2:	95 ºC	 10 mins
Step 3:	95 ºC	 15 secs
	60 ºC		1 min
Step 4: (dissociation)	95 ºC	 15 secs
	60 ºC		1 min
	95 ºC	 15 secs

Fig. 2.4: Details of PCR cycles: A single cycle of step 1 and 2, followed by 40 cycles of step 3. This was then followed by a dissociation stage, a single cycle of step 4.


Cycle thresholds (CT) were determined using 7500 System SDS software Version 1.3 (Applied Biosystems). Control and p63 siRNA sample triplicates were accepted for analysis where the standard deviation of CT measurements from the three replicates was < 0.3. 


Table 2.19: Reaction mixture for qRT PCR, using SYBR® Green PCR Master Mix.

Component	Initial concentration	Volume (μl)








In order to assess the efficiency of the qRT PCR reaction and allow quantification of relative expression of each target gene in p63 knock down samples as compared with controls, the ddCT method was employed. An internal control was run alongside the samples using 18s primers. Mean Ct values for the internal control was subtracted for that of each target gene, in control and p63 knock down samples. The differential gene expression was used to calculate ddCT values using mean cycle thresholds in Microsoft Office Excel®. Relative fold changes for each target gene were determined accordingly. Results were expressed on a log scale to illustrate upregulation or downregulation for each gene, using GraphPad Prism®.


2.13 Immunohistochemistry of primary human cancer specimens
All histology and IHC was kindly performed by Mohammed Ikram and Keyur Trivedi (Molecular Pathology Service, CRUK Centre, Queen Mary University of London) and all slides reviewed by NC and YW. Anti-human p63α was used to determine the distribution of human p63 protein expression in primary human oral squamous cell carcinoma and pancreatic ductal adenocarcinoma tissues. Isoform-specific expression of ΔNp63α was confirmed with anti – p40 (∆Np63) staining, done in conjunction with anti - p63α staining. 

2.13.1 Sample processing
4μm serial sections from formalin-fixed, paraffin-embedded blocks of tumour-representative areas were cut for each case using a Leica CM1900 microtome (Leica Microsytems, Wetzlar, Germany). Immunohistochemistry was performed on sections mounted on poly-L-lysine coated glass slides. IHC staining with anti - p63α was performed using the Ventana® Discovery staining module (Ventana, Tucson, USA). This system produced a dark brown substrate on light microscopy.









Table 2.20: Primary antibodies used for IHC for primary human tissues. 

Antibody	Species	Optimised dilution	Supplier





2.14 Data handling and statistical analysis
2.14.1 EC50 and variable slope non-linear regression
EC50 = ((X where Y=top) – (X where Y= bot tom))*0.5
Y= Bottom +   ____(Top-Bottom)____
(1+10((LogEC50-X)*HillSlope))
X = log[virus] ;Y =  %cells alive; Hillslope=steepness of curve
Top/Bottom = Maximum/Minimum Y value (or cell death)

2.14.2 ddCT
The Delta-Delta-Ct (ddCt) Algorithm was used as an approximation method to determine relative gene expression from qPCR experiments. The threshold cycle (CT), which is associated with a significant increase in the fluorescence signal associated with exponential growth of PCR product, is used for the calculation. 

The calculations for quantification begin with determining the difference between the CT values (∆CT) of the target and the reference (internal control):

∆CT = CT (target) - CT (internal control)

This value is calculated for each triplicate sample to be quantitated.
 
The comparative ∆∆CT calculation involves finding the difference between each test sample's ∆CT (TP63 siRNA) and the control’s ∆CT (control siRNA). The last step in quantitation is to transform these values to absolute values. The formula for this is:
 
comparative expression level = 2 - ∆∆Ct

2.14.3 Statistical analyses
Data are expressed as a mean +/- standard deviation (sd) of a given number of observations. 

Data sets were analysed to determine if differences between them were statistically significant. Statistical analysis was done using unpaired T-tests, or ANOVA exact tests as appropriate with p<0.05 considered significant.

Kaplan-Meier survival analysis was used to compare survival studies.




















Clinical implications of p63 expression in primary oral squamous cell carcinoma (OSCC) and pancreatic ductal adenocarcinoma (PDAC)


3.1 p63 expression in normal oral squamous epithelium and oral squamous cell carcinoma











p63 expression was revealed as brown nuclear staining. The immunohistochemical analysis showed that p63 was expressed in the basal and suprabasal epithelial layers of normal oral squamous tissue. Its expression was gradually lost as the epithelial cells were increasingly differentiated.

p63 was also expressed in a continuum of neoplastic lesions, ranging from early dysplasia to advanced cases of poorly differentiated invasive carcinoma. The observed p63 staining pattern was found to differ according to the grade of neoplasm. The distribution of p63 expression in well differentiated cases was similar to that of normal tissue. That is to say, it was also expressed in the basal and suprabasal layers of squamous cells in cases of dysplasia and well differentiated carcinomas. Expression was lost as the cells were more differentiated towards the centre of the tumour islands.  In moderately differentiated tumours, the p63 staining was still restricted to predominantly basal epithelial layers but more diffuse. In the cases of poorly differentiated carcinomas, there was strong p63 staining in all the tumour cells of the infiltrative cancers, but the pattern of staining was lost along with the loss of normal tissue architecture.

This pattern of p63 staining observed in normal and neoplastic oral squamous epithelial cells is consistent with other reports that have evaluated p63 expression in this tumour model [218].

 
3.2 p63 expression in primary human pancreatic ductal adenocarcinoma









Fig. 3.2: Immunohistochemical expression of p63 in primary pancreatic tissue; 4A4 antibody was used for p63 immunoreactivity.




3.3 Determination of p63 antibody specificity
3.3.1 Evaluation of 4A4 antibody




Fig. 3.3: Efficiency of 4A4 antibody in differentiating between p63 isoforms. Western blot showing the different p63 isoforms detected by 4A4 antibody. PCNA was used as a loading control.

The first lane with lysate of cells transfected with empty vector pc3.1 served as a negative control and did not show any p63 expression, as expected. Of the remaining lanes, those representing MCF-7 cells transfected with TAp63α, ΔNp63α, ΔNp63β and ΔNp63γ, all showed strong bands representing positive p63 expression, except lane 5. Lane 5 represented cells transfected with TAp63γ and did not reveal any significant band. The plasmid pcTAp63γ used for this transfection was subsequently sequenced, which revealed that the ATG start codon was absent (data not included), thus not enabling the TAp63γ protein to be translated. However, the Western blot otherwise suggested that the 4A4 antibody had wide specificity for p63. It was able to detect all p63 isoforms and this would suggest that it was not able to differentiate the precise isoform that was upregulated in the two tumour models tested. 

3.3.2 Evaluation of additional p63 antibodies














Fig. 3.4: Efficiency of anti-p63α and anti-ΔNp63 antibodies. Western blots showing the specificity of the p63α and ΔNp63 antibody in differentiating between p63 isoforms. Antibodies used are denoted in blue. PCNA was used as a loading control.

The anti-p63α antibody detected TAp63α and ΔNp63α and therefore showed specificity for all α-isoforms. The anti-ΔNp63 antibody detected ΔNp63α, ΔNp63β and ΔNp63γ, and therefore demonstrated specificity for ΔNp63 isoforms. Put together, these two antibodies can be used to confirm if it is the ΔNp63α isoform overexpressed in the two tumour models tested.


3.4 ΔNp63α overexpression in primary pancreatic and oral squamous cell carcinomas




















Fig. 3.5: Immunohistochemistry of primary (A) OSCC and (B) PDAC specimens with anti-p63α and anti-ΔN antibodies (denoted in blue); samples were stained with the two antibodies in parallel. Symmetrical images confirm ΔNp63α was the predominant isoform overexpressed in primary OSCC and PDAC. 


Immunohistochemistry staining with these two antibodies showed a   symmetrical pattern of p63 staining in all samples, from both OSCC and PDAC specimens. The parallel images of serial sections stained with the two different antibodies confirm that ΔNp63α was the predominant isoform that was upregulated in these two tumour types. 


3.5 Correlation of p63 staining with clinicopathological features in PDAC 
As normal pancreatic tissue did not express p63, the clinical implications of ΔNp63α expression in pancreatic cancer were further evaluated. The expression of ΔNp63α in 63 primary pancreatic ductal adenocarcinoma specimens was analysed by immunohistochemistry and this was correlated to clinicopathological features. Moreover, the ability of p63 to act as a potential biomarker to predict prognosis was reviewed.

A total of 63 samples from paraffin-embedded specimens of primary human pancreatic ductal adenocarcinoma were used for the study. Each sample was stained with 4A4 antibody for examination of p63 expression. Only nuclear staining of epithelial cells was included for analysis. To determine the amount of p63 expressed in each sample, a semi-quantitive assessment was employed to score each specimen. This was performed independently by two assessors who were blinded to the clinicopathological data (NC and YW). A mean percentage of positive nuclei derived from 15 random areas at x200 magnification was determined for each sample. Each case was then scored into one of four categories. They were graded as follows:

0:     no staining
+:     1% to 10% staining
++:   11% to 50% staining
+++: 51% or more staining


The study population of 63 cases comprised 26 females and 77 males, with a mean age of 62 years (range 32 to 79 years). 

3.5.1 Evaluation of p63 expression as a potential prognostic biomarker 
The data were first analysed to determine any prognostic significance of p63 expression in primary PDAC patients. Therefore, the correlation of any p63 staining with survival was assessed. Survival was calculated from the date of diagnosis to the date of the latest clinical follow-up or death by disease. 




Table 3.1: Comparison of p63 staining score with survival. Patient survival was correlated to negative and positive staining for p63. Chi-squared test was used for statistical analysis.


p63 score	0 / +	++ / +++




















Fig. 3.6: Correlation of p63 expression and survival in PDAC patients. Kaplan-Meier survival curve comparing no staining and positive p63 expression with overall survival. Arrows indicate median survival for the two groups of patients.


However, further analysis of the data revealed that there were a number of patients with very low levels of p63 staining, who appeared to preserve a survival advantage. The data were therefore re-analysed to compare patients with ‘low’ p63 staining, which comprised all those with 10% or less positive staining (0 / +), or ‘high’ for those with 11% or more staining (++ / +++) (Fig. 3.7). 


Fig. 3.7: Representative samples of human PDAC specimens with ‘low’ or ‘high’ p63 expression; images were taken at x200 magnification.






Table 3.2: Comparison of ‘high’ or ‘low’ levels of p63 staining score with survival. Chi-squared test was used for statistical analysis.


p63 score	0 / +	++ / +++














































Fig. 3.8: Correlation of variable levels of p63 expression and survival. Kaplan-Meier survival curve comparing ‘low’ and ‘high’ p63 expression and overall survival. Arrows indicate median survival for the two groups of patients.


3.5.2 Correlation of p63 expression with clinicopathological features















Table 3.3: Correlation of p63 expression and clinicopathological features. Statistical analysis was performed using Pearson Chi – Squared test.

Clinical features	Patient No. (N=63)	    p63 staining	P value

































Biological implications of ΔNp63α in human HNSCC and PDAC in vitro

4.1 Introduction
The earlier results presented in this study confirm that ΔNp63α is upregulated in both primary human head and neck squamous cell carcinomas and primary human pancreatic ductal adenocarcinomas. Most importantly, the immunohistochemistry analysis has shown that overexpression of ΔNp63α is associated with a significantly worse overall survival. This result in itself warrants further evaluation of the functional effects of ΔNp63α in cancer. 

In order to investigate the functional role of ΔNp63α on tumour biology, a panel of pancreatic cancer and head and neck cancer cell lines were screened for p63 expression. p63-overexpressing cell lines were selected to conduct functional studies and compared with derivatives ‘knocked down’ for p63, using TP63 siRNA. Using this approach, the effects of ΔNp63α on tumourigenicity, migration, invasion and chemosensitivity were determined.
 
4.2 p63 overexpression in pancreatic and head and neck cancer cell lines





Fig. 4.1: p63 protein expression in a panel of human cancer cell lines. Western blots were used to screen for p63 overexpression in a panel of human cell lines; (A) pancreatic cancer cells lines, (B) head and neck cell lines. 4A4 antibody was used to probe for p63 and PCNA was used as a loading control.









Fig 4.2: Confirmation of p63 isoform expression in human cell lines. Western blot showing ΔNp63α is overexpressed in one pancreatic and two head and neck cancer cell lines. The band representing overexpressed ΔNp63α (lane 3) is detected at the same molecular weight as the bands noted in parental cell lines that were mock-transfected (lane 1) and those transfected with pc3.1 (lane 2), thus confirming that ΔNp63α is the predominant isoform that is upregulated. p63α was used to probe for p63 and PCNA was used as a loading control.

For all cell lines transfected with ΔNp63α, there is a denser band in lane 3, which is at the same molecular weight as the bands observed in lanes 1 and 2, (mock-transfected and control plasmid-transfected respectively). This confirms that ΔNp63α is the predominant isoform that is upregulated in these human cancer cell lines.


4.3 shRNA vectors for stable p63-silenced cell line 
Pre-designed TP63 human shRNA contructs (OrigeneTM) were used to deliver ΔNp63α gene knockdown in MiaPaca 2 cells. Four TP63 human shRNA constructs were obtained from OrigeneTM and validated by Dr Ming Yuan (MY) using transient transfection (Effectene®, QiagenTM; section 2.2.3), in order to determine their individual efficiencies in gene silencing. Of these, the most efficient TP63 shRNA expression cassette was cloned into the retroviral vector pRS (OrigeneTM) by MY, which can be used for both transient and stable transfection. A pRS vector carrying a 29-mer scrambled sequence cassette was used as negative control (Origene TM).








Fig. 4.3: Silencing efficiency of pRS TP63 shRNA. (A): Transient transfection with pRS TP63shRNA demonstrates efficient gene silencing in lane 3 as compared to cells with mock transfection and control vector transfections, in lanes 1 and 2 respectively. (B): Stable transfection with pRS TP63shRNA does not demonstrate any p63 silencing. p63α antibody was used to probe for p63 and PCNA was used as a loading control. 


4.4 p63 silencing by siRNA
Pre-designed double stranded siRNA oligonucleotides were used for gene knockdown experiments. Sequence-specific TP63 siRNA was obtained from Dharmacon Research. This consisted of four targeting sequences for p63 (Table 2.3), and these were used as a Custom SMARTTM pool to knockdown endogenous ΔNp63α in selected p63-overexpressing cell lines. A non-targeting RISC-free® control sequence (Dharmacon Research), with impaired ability for RISC interaction, was also used as a non-silencing negative control.













Table 4.1: Summary of optimised DharmaFECT® transfection reagents. For cell lines that were verified by NC, the preferred, optimal transfection reagent is recorded. Cell lines that had been previously optimised within the department (‘other’) or by Dharmacon®, were not further evaluated.

Human tumour type	Cell line	Optimal transfection reagent	Source of verification
Pancreatic	MiaPaca 2	DharmaFECT® no. 2	Dharmacon TM
	Suit-2	Dharma FECT® no. 2	NC
Head and neck	Fadu	DharmaFECT® no. 1	NC
	SCC 25	DharmaFECT® no. 2	Other
	SCC 4	DharmaFECT® no. 1	NC
	TR 126	DharmaFECT® no. 1	Other
	TR 138	DharmaFECT® no. 2	Other


4.5 Evaluation of silencing efficiency of TP63 siRNA
The silencing efficiency of TP63 SMARTpool siRNA was examined by transient tranfections in MiaPaca 2, a p63 overexpressing cell line. Following transient transfection with non targeting RISC-free® control siRNA and TP63 siRNA, using DharmaFECT® transfection reagent 2 (Table 4.1), the efficiency of gene knockdown was determined between timepoints 0 to 144hours (Fig. 4.5). This confirmed that p63 was effectively silenced by TP63 SMARTpool siRNA compared to that of the non-targeting RISC-free control siRNA. In MiaPaca 2 cells, almost complete p63 knockdown was observed from 24 hours and this effect was long-lasting, persisting until 144 hours.

Fig. 4.5: Silencing efficiency of TP63 siRNA in MiaPaca 2 cells. Western blot showing ΔNp63α knockdown as compared with control cells, between timepoints 0 to 144 hours. ‘C’ indicates cells transfected with non targeting RISC-free® control siRNA and ‘si’ indicates cells transfected with TP63 SMARTTM pool siRNA. Anti-p63α antibody was used to probe for p63 and β actin was used as loading control.  


In order to determine if this effect was reproducible, this was repeated in an alternative human head and neck cancer cell line, Fadu. The efficiency of p63 knockdown was tested at ‘early’ timepoints (24 – 72 hours) and a single ‘late’ timepoint (144 hours). This similarly confirmed highly effective and efficient p63 knockdown, that was also durable (Fig. 4.6). 

Put together, these results suggest that the silencing effect of TP63 Custom SMARTTM pool siRNA occured very quickly, starting from within the first 24 hours post-transfection, and that it occurs in a time-dependant manner, with a long-lasting effect persisting to 144 hours.   


Fig. 4.6: Silencing efficiency of TP63 siRNA in Fadu cells. Western blot showing ΔNp63α knockdown as compared with control cells, at ‘early’ timepoints (24 to 72 hours) and a ‘late’ timpoint (144 hours). ‘C’ indicates cells transfected with non targeting RISC-free® control siRNA and ‘si’ indicates cells transfected with TP63 SMARTTM pool siRNA. Anti-p63α antibody was used to probe for p63 and PCNA was used as loading control.  


4.6 Effect of ΔNp63α expression on anchorage independent growth
Anchorage-independant growth is an important characteristic of malignant cells in vitro. The ability of tumour cells to proliferate without firm attachment is a strong indicator of tumorigenicity. Therefore, to determine whether ΔNp63α expression influenced such growth, cells were grown in soft agar for several weeks. 






Fig 4.7: Effect of ΔNp63α expression on anchorage independent growth. Soft agar colony formation assay on cell lines treated with control siRNA and TP63 siRNA in MiaPaca 2, Suit-2 and Fadu cells, and overexpression in PT45 and Panc 1 cells. (A): Soft agar plates showing representative colonies for control and treated cells. (B): Quantitative analysis of colony formation. Values represent mean number of colonies formed from triplicate experiments +/- SEM. Statistical differences were calculated using Unpaired t test (*** P<0.001). (C): Western blot showing p63 knockdown or overexpression of p63.
4.7 Effect of ΔNp63α expression on tumour cell proliferation
The effect of ΔNp63α on cell proliferation was investigated using cell growth assays. Several p63-overexpressing cell lines were used for p63 knockdown experiments (section 2.3.3). In addition, PT45, a p63 non-expressing cell line was used for ΔNp63α overexpression (section 2.2.3). 24 hours following transient transfection, all cells were harvested and seeded in triplicate, into 24 well plates (time 0 hours). Cell proliferation was measured daily over a five to seven day period by Coulter counting (section 2.6.2). Cell growth curves were plotted for each cell line, to confirm the effect of p63 expression on proliferation (Fig. 4.8) 














4.8 Effect of ΔNp63α expression on tumour cell migration
The effect of ΔNp63α on tumour cell migration was studied using transwell migration inserts containing 8μm porous PET (polyethylene tetraphthallate) membranes. A panel of p63-overexpressing cell lines were used to conduct p63 knockdown experiments (section 2.3.3). In addition PT45 cells were used for overexpression of ΔNp63α along with control vector transfection (section 2.2.3). At 24 hours following transfection, cells were plated into transwell chambers. 50,000 cells were seeded into the upper chambers in serum-free medium and cell migration was directed towards complete medium within the lower chambers. After a further 24 hours, cell migration through the PET membrane was measured (section 2.7.2). Replicates of three or more were used for each cell line and each experiment was repeated on three separate occasions (Fig. 4.9).







Fig. 4.9: Effect of ΔNp63α expression on cell migratory potential in (A) pancreatic and (B) head and neck cancer cell lines. Transwell hapoptactic migration assays were used to compare cell migration in a panel of cell lines used for p63 knockdown experiments and also ΔNp63α overexpression in PT45 cells (A) was also used to cell migration assay. The total number of cells that had migrated through the porous PET membrane, after 24 hours, was counted. Values represent mean numbers of migrated cells from three or more replicates from a single experiment +/- SEM. Statistical differences were calculated using Two-way ANOVA test (* P<0.05, ** P<0.01).
4.9 Effect of ΔNp63α expression on tumour cell invasion 
In view of recent evidence supporting a role for ΔNp63α in regulating invasion in human cancer cell lines [203], [204], its effect in human pancreatic cancer cell lines was evaluated, along with a panel of head and neck cancer cell lines. The effect of ΔNp63α on invasion was validated by two methods in vitro, using transwell invasion assays and organotypic cultures. 

4.9.1 Transwell invasion assay
The invasive potential of cells treated with siRNA, was measured using BD BiocoatTM MatrigelTM (BD Bioscience®) invasion chambers. 50,000 cells were suspended in serum-free medium in the upper inserts containing 8μm porous PET membrane, pre-treated with MatrigelTM. This serves as a reconstituted basement membrane in vitro. The uniform layer occludes the pores of the membrane, thereby blocking non-invasive cells from migrating through. By contrast, invasive cells are able to detach themselves from and migrate through the MatrigelTM treated membrane. 

Cell invasion was measured at 48 hours, to prevent any potential differences in invasion being attributed to a pro-proliferative effect of ΔNp63α, which was confirmed from 72 hours and after in the cell lines that were examined (section 4.6). Therefore, 48 hours following transfection, cells on the undersurface of the membrane were trypsinised and cells that had invaded through the MatrigelTM were counted using the Coulter counter (section 2.8.2). Replicates of four or more were used for each cell line and each experiment was repeated on three separate occasions (Fig. 4.10).



















4.9.2 In vitro three-dimensional culture
Transwell invasion assays represent a simple approach to studying invasion. However, these frequently show considerable experimental variability and furthermore, they fail to represent an in vivo-like tumour microenvironment. Organotypic culture models now allow closer patterns to in vivo cell behaviour to be analysed, in particular between tumour cells and stromal fibroblasts. 

Three-dimensional organotypic cultures were used to compare the invasive potential of cell lines transfected with control and TP63 siRNA (section 2.3.3). Briefly, organotypic gels were prepared by suspending fibroblasts in a 1:1 mixture of type I collagen (Upstate Cell Signalling Solutions) and MatrigelTM (BD Biosciences®), with 10X DMEM medium containing foetal calf serum (Section 2.9.1). The gel solution was pipetted into 24 well plates (1ml/well) and allowed to polymerise for one hour at 37ºC, before adding 1ml culture medium to each gel. 24 hours following siRNA transfection, 5x105 cells were suspended in complete culture medium and seeded onto the organotypic gels. They were incubated at 37ºC for a further 24 hours, after which the gels were removed from the 24 well plates and placed onto individual collagen-coated nylon discs, resting on steel grids (section 2.9.2; Fig. 2.1). These were placed in 6 well plates with growth medium added until the fluid level reached the undersurface of the grids. Gels were incubated for seven days and culture medium changed every second day. Finally, the gels were fixed and embedded in paraffin, and stained with hemotoxylin-eosin (HE); (Fig. 4.11). Duplicates were used for each cell line tested, and each experiment was repeated twice, on separate occasions.







Fig 4.11: In vitro three-dimensional culture of cells transfected with TP63 siRNA in (A) pancreatic and (B) head and neck cancer cell lines. Paraffin sections from in vitro three-dimensional organotypic assays were stained with H&E. The effect of ΔNp63α on the invasive properties of cells was evaluated.  

4.10 Chemosensitivity of parental tumour cells














Table 4.2: Summary of sensitivity of human tumour cell lines to chemotherapy agents. Pancreatic cancer cell lines were treated with 5 FU and gemcitabine, and head and neck cell lines with 5 FU and cisplatin. Mean EC50 (drug dose required to kill 50% of cells) values were derived from MTS assay.













4.11 Effect of ΔNp63α expression on chemosensitivity 

















Table 4.3: EC50 values by MTS assay 72 hours after drug treatment. Statistical analysis using Unpaired T test was used to determine P values for the difference in sensitivity of each cell line according to p63 expression.


Human tumour type	Cell line	Drug	Control siRNA	TP63 siRNA	P value










p63 expression was observed to affect drug cytotoxicity in all cell lines tested. Depletion of p63 resulted in significantly enhanced sensitivity to both 5-FU and gemcitabine for both pancreatic cell lines. Therefore, it would seem that p63 expression confers some degree of resistance to both these drug treatments in MiaPaca 2 and Suit-2 cells and that suppression of p63 enables increased chemosensitivity. However, conversely, in the head and neck cell line Fadu, p63 knockdown did not demonstrate any significant effect on chemosenitivity to 5-FU. Also, interestingly, although p63 expression did impact on sensitivity to cisplatin, the reverse effect was noted. That is to say, that expression of endogenous ΔNp63α was found to increase sensitivity to cisplatin, and therefore mediate enhanced sensitivity specifically to this treatment.    

These results demonstrate that downregulation of ΔNp63α by siRNA can affect the sensitivity to conventional chemotherapy treatments, in a tumour-specific manner. In the head and neck cancer cell line that was tested, endogenous ΔNp63α expression would appear to increase tumour cell killing response to cisplatin. Conversely, depletion of ΔNp63α in the two human pancreatic cancer cell lines resulted in greatly increased sensitivity to both 5-FU and gemcitabine treatments, and these results were highly statistically significant. As these drugs function by impacting on the cell cycle, this raises the question as to whether p63 knockdown induces synergy in these regulatory processes. 

4.12 Role of apoptotic pathways in regulating the interaction between p63 and chemotherapy 
The data presented so far have demonstrated that depletion of ΔNp63α induces synergy in tumour cell killing with chemotherapy drug treatments, and this was most significant in the MiaPaca 2 cell line. This result is potentially of great clinical significance and therefore warrants further exploration. The effect of ΔNp63α expression on sensitivity to chemotherapeutic agents in MiaPaca 2 cells was therefore further evaluated.  





Fig 4.14: Apoptotic screen in MiaPaca 2 cells, treated with chemotherapeutic drugs following p63 suppression. ‘C’ indicates cells transfected with control RISC free non-targeting siRNA and ‘si’ indicates cells transfected with TP63 siRNA. 5-FU and gemcitabine were added to cells, 48 hours following transfection. Cell lysates were collected between 6 and 48 hours post drug treatment, for Western blot, to screen for apoptotic markers to evaluate the mechanism mediating synergy between p63 knockdown and chemotherapy. PCNA was used as a loading control.  

For MiaPaca 2 cells treated with both 5-FU and gemcitabine, there was clear, increased induction of PARP cleavage in p63 knockdown cells, as compared with control p63 expressing cells. This was evident very quickly after drug treatment, as the Western blot demonstrates that this began to occur as early as 6 hours post treatment and became more pronounced with time, and this was true for both chemotherapeutic agents (Fig. 4.13). Such induction of PARP cleavage however, was not clearly associated with changes in total PARP levels, suggesting that total PARP maybe continually being replenished within cells in parallel with PARP cleavage. There was however, upregulation of caspase 3 seen in p63 knockdown cells treated with both 5-FU and gemicitabine, as compared with controls and this also appeared to occur in a time dependent manner. This activation of caspase 3 would be in keeping with increased cleaved PARP production, and together this would suggest that downregulation of p63 enhances the sensitivity of MiaPaca 2 cells to 5-FU through induction of this pro-apoptotic pathway. Interestingly, for p63 knockdown cells treated with gemcitabine, activation of caspase 3 and PARP cleavage occurred up to 24 hours but beyond this time-point, there was no further activation of this apoptotic pathway. However, this pathway appeared to be persistently activated in p63 knockdown cells treated with 5-FU even at 48hours. 









Evaluation of a ΔNp63α-dependent transcription profile

5.1 Introduction
In order ultimately to be able to explore which cellular pathways are activated in ΔNp63α-expressing cells, microarrays were utilised to create a ΔNp63α-dependent transcription profile, initially in a human pancreatic cancer-derived cell line. ΔNp63α-overexpressing MiaPaca 2 cells were compared with derivatives ‘knocked down’ for ΔNp63α, using RNA interference (RNAi) technology. Statistical comparisons between non-silencing control siRNA and p63-targeting siRNA groups were used to identify a gene expression profile list of transcriptional targets for ΔNp63α. A selection of target genes was validated and their functional effects on tumour biology studied. 


5.2 Microarray gene expression profile
5.2.1 Sample preparation for Microarray gene expression profile analysis





Fig. 5.1: Efficiency of p63 knockdown in samples used for microarray analysis. Western blot of cell lysates obtained from MiaPaca 2 cells transfected with control and TP63 siRNA. S1, S2, S3 and S5 denote samples obtained from individual, independent transfection experiments carried out on four separate occasions. ‘C’ indicates control cells transfected with non targeting RISC free control siRNA and ‘si’ denotes cells transfected with TP63 siRNA. p63α antibody was used to probe for p63 and PCNA was used as a loading control.


5.2.2 ΔNp63α-dependent transcriptional signature
Microarray gene expression profiling using three independent samples (S2, S3 and S5) of MiaPaca 2 cells transfected with control and TP63 siRNA was performed using Affymetrix U133 Plus 2.0 array. A detailed description of the array procedure is described in Materials and Methods (section 2.11). Briefly, total RNA was extracted from MiaPaca 2 cells, 48 hours following transient transfection. Total RNA was used for reverse transcription to synthesise first strand cDNA. cDNA was converted to double-stranded cDNA template or aRNA. This was biotinylated and purified, and after fragmentation, the biotin-labelled aRNA was hybridised to GeneChips®. The chips were scanned using the GeneArray Scanner 3000 (scanning and image analysis was kindly performed by Tracy Chaplin, Institute of Cancer, Queen Mary University of London). Each experiment was performed in biological triplicates to allow appropriate statistical analysis.  

Data acquired from gene expression profiling was kindly analysed by Dr Claude Chelala, (Lecturer in Cancer Bioinformatics, Institute of Cancer, Queen Mary University of London). Significant changes in gene expression were observed after silencing ΔNp63α (Appendix 1) and are summarised in Table 5.1. Many genes regulated in these experiments were represented by multiple probe sets, and therefore the actual number of genes differentially expressed is indicated separately in brackets. 

Table 5.1: Summary of gene expression changes following p63 silencing. Changes in probe sets between non-silencing control siRNA-treated cells and TP63 siRNA-treated cells. Number of genes represented is indicated in brackets.

Differential gene expression	P < 0.05
Total probe sets (genes) differentially regulated	330 (237)
Total probe sets (genes) downregulated	241 (157)
Total probe sets (genes) upregulated	89 (80)


The data were analysed for positive and negative fold-changes (≥+1 or ≤-1) and also statistical significance using a 5% confidence interval. In total, 237 gene expression changes were identified (p<0.05). A list of the 30 most significantly down and up-regulated probe sets is outlined in Table 5.2.

Encouragingly, within these significant expression changes, probe sets specific to TP63 were also affected, as highlighted in turquoise in Table 5.2. As expected, TP63 transcript levels were down-regulated and demonstrated one of the greatest fold-changes, in response to TP63-targeting siRNA, thereby supporting the validity of the microarray results. 








Table 5.2: Significant gene expression changes following p63 silencing. Most significant changes observed in the probe sets between cells transfected with non-silencing control and TP63 siRNA are illustrated. (A): 30 gene expression profile changes with greatest order of downregulation; (B): 10 gene expression profile changes with greatest order of upregulation. Genes highlighted in yellow indicate candidate genes selected for validation. Gene highlighted in turquoise represents p63 itself.





226810_at	6q13	OGFRL1	opioid growth factor receptor-like 1	-2.80
209863_s_at	3q28	TP63	tumor protein p63	-2.62
228582_x_at	11q13.1	MALAT1	metastasis associated lung adenocarcinoma transcript 1 (non-protein coding)	-2.55
227776_at	11q13.5	PHCA	phytoceramidase, alkaline	-2.18
228306_at	1q42.11	CNIH4	cornichon homolog 4 (Drosophila)	-2.16
226279_at	11q14.1	PRSS23	protease, serine, 23	-2.11
226853_at	4q21.21	BMP2K	BMP2 inducible kinase	-2.02
222663_at	5q15	RIOK2	RIO kinase 2 (yeast)	-2.00
213626_at	4q32.3	CBR4	carbonyl reductase 4	-1.97
223089_at	12q22	VEZT	vezatin, adherens junctions transmembrane protein	-1.93
205036_at	4q31.22	LSM6	LSM6 homolog, U6 small nuclear RNA associated (S. cerevisiae)	-1.91
224985_at	1p13.2	NRAS	neuroblastoma RAS viral (v-ras) oncogene homolog	-1.90






224596_at	9q31.2	SLC44A1	Solute carrier family 44, member 1	-1.74
212397_at	11q23	RDX	Radixin	-1.66
209434_s_at	4q12	PPAT	phosphoribosyl pyrophosphate amidotransferase	-1.65
224843_at	4p12	SLAIN2	SLAIN motif family, member 2	-1.64
227299_at	4q21.1	CCNI	Cyclin I	-1.64
235635_at	14q12	ARHGAP5	Rho GTPase activating protein 5	-1.61
235754_at	6p21.3	HFE	Hemochromatosis	-1.58
225996_at	2q11.2	LONRF2	LON peptidase N-terminal domain and ring finger 2	-1.57
200969_at	3q25.1	SERP1	stress-associated endoplasmic reticulum protein 1	-1.57
201017_at	Xp22.12	EIF1AX	eukaryotic translation initiation factor 1A, X-linked	-1.55
209780_at	7q11.23-q21	PHTF2	putative homeodomain transcription factor 2	-1.54





(B): Gene list of 10 gene expression profile changes with greatest magnitude of upregulation, following p63 silencing.

Affymetrix probe	MAP	Symbol	NAME	Fold Change
233292_s_at	5q31.3	ANKHD1	ankyrin repeat and KH domain containing 1	1.30
214895_s_at	15q2; 15q22	ADAM10	ADAM metallopeptidase domain 10	1.35
1553694_a_at	11p15.5-p14	PIK3C2A	phosphoinositide-3-kinase, class 2,           alpha polypeptide	1.37
221194_s_at	17q23.1	RNFT1	ring finger protein, transmembrane 1	1.38
203626_s_at	5p13	SKP2	S-phase kinase-associated protein 2 (p45)	1.40
225446_at	21q22.2	BRWD1	bromodomain and WD repeat domain containing 1	1.43
209629_s_at	Xq22.3	NXT2	nuclear transport factor 2-like export factor 2	1.45
203890_s_at	19p13.3	DAPK3	death-associated protein kinase 3	1.46
1555830_s_at	7q36.3	FAM62B	family with sequence similarity 62       (C2 domain containing) member B	1.51





5.2.3 Validation of selected Affymetrix gene expression changes
In order to assess the reliablilty of the microarray gene expression profile generated following ∆Np63α silencing in MiaPaca 2 cells, a selection of genes were further evaluated. A total of seven transcriptional targets were chosen based on the magnitude and statistical significance of their microarray-derived gene expression values and their potential biological interest with respect to carcinogenesis. These included five genes that were downregulated and two that were upregulated from the microarray gene expression profile analysis.

5.2.3.1 qRT PCR validation
Quantitative real-time polymerase chain reaction (qRT PCR) was used to confirm the relative expression of mRNA of the seven selected target genes. cDNA was synthesised from RNA pellets from MiaPaca 2 cells transfected for 48 hours with control and TP63 siRNA , using reverse transcriptase (section 2.12.2). Pre-designed primers for the seven target genes identified from Microarray analysis (section 2.12.3) were used for qRT PCR, using the SYBR® Green PCR system (section 2.12.4). Samples and no-template controls (RNase free water) were tested in triplicate and cycle thresholds (CT) were determined using 7500 System SBS software (Applied Biosystems, New Jersey, USA). qRT PCR was repeated on three separate occasions.
The ddCT method was used to quantify relative expression of each target gene in p63-knockdown samples as compared with controls (section 12.14.2) An internal control was run alongside the samples using 18s primers. Relative fold-changes for each target gene were determined accordingly (section 2.13.2). Results were expressed on a log scale to illustrate upregulation or downregulation for each gene, using Microsoft Office Excel package (Fig. 5.3). Overall, this validation demonstrated good correlation with the expected gene expression changes at the transcriptional level for the seven selected genes, when compared with the microarray data (Table 5.2). There was notable downregulation of three genes, namely OGFRL1, BMP2K and PRSS23. These three genes also had the greatest order of negative gene expression changes from the candidate genes selected for validation, as compared with microarray, following TP63 knockdown (Table 5.2). 

DAPK3 and SKP2 also showed notable upregulation in mRNA levels following p63 knockdown, also supporting the microarray data. 












5.2.3.2 Western blot validation
In order to confirm if any of the selected microarray gene expression changes could be confirmed at the protein level, Western blot analysis was conducted. Based on the qRT PCR data analysis, two genes that were differentially downregulated according to p63 expression were chosen for further analysis. These included PRSS23 and BMP2K, as there is very little if any published literature available on these two genes or any potential implications in carcinogenesis. Although OGFRL1 was the most significant gene expression change from microarray, and this was validated from qRT PCR results, OGFR is already a previously well identified player in cancer, with a number of recently published reports confirming its effect in restricting cellular proliferation [240] [241],[242]. Therefore, for the purpose of this study further work was limited to the other two genes that were significantly downregulated following TP63 knockdown, PRSS23 and BMP2K, both of which are to date unknown entities in cancer. 
Of these two genes, there was no available antibody to probe for differential PRSS23 expression, at the time this study was conducted. Only BMP2K had a commercially available antibody available and could therefore be further validated by Western blot (section 2.4; Fig. 5.4).
 

Fig. 5.3: Validation of BMP2K expression changes by Western blot. MiaPaca 2 cells were transfected as indicated and whole cell extracts were harvested at 48 hours. MCF 7 cells were used as a positive control for BMP2K. All protein lysates were prepared and fractionated by SDS/PAGE and blotted to membrane, which was probed with primary p63α and BMP2K antibodies. PCNA was used as a loading control.


BMP2K (BMP-2 inducible kinase) is a protein kinase with a putative regulatory role affecting bone morphogenic proteins (BMPs). It has a predicted molecular weight of 129kDa. The positive band in lane 1 representing MCF 7 lysates, which served as a positive control, confirms that the BMP2K antibody used was functioning correctly to detect BMP2K protein expression. However, there was no clear band representing any change in protein levels in the test lanes representing MiaPaca 2 cells treated with control and TP63 siRNA (lanes 2 and 3 respectively). This would suggest that although there is significant differential expression of BMP2K on microarray and qRT PCR analysis, this difference is confirmed at transcriptional level, but potentially not translated to changes in protein expression. 


5.3 Functional effects of selected microarray-detected genes
In the earlier work presented in this study, the clinical and biological implications of ∆Np63α have been extensively evaluated. The results presented so far have confirmed that it is clearly implicated in tumourigenesis in the two tumour models studied, but more importantly, that it is of clinical significance, by affecting overall prognosis in pancreatic cancer patients. It was therefore considered relevant to attempt to further elucidate its contribution, firstly by identifying some notable downstream target genes through which it may mediate its effects. 

Having conducted validation experiments of some of these genes using qRT PCR and Western blot where possible, it was decided to further evaluate the functional effects of PRSS23 and BMP2K. Although differential expression of these two genes was not satisfactorily validated at the protein level, the qRT PCR results (Fig. 5.3) did confirm that they were at the very least differentially expressed at the mRNA transcript level, according to the degree of p63 expression. As p63 is a known transcription factor, this transcriptional effect on both PRSS23 and BMP2K mRNA is of potential significance. Therefore, the effects of expression of these two genes on cell growth, migration and chemosensitivity were further analysed. These three tumour functions were selected as the earlier work in this study has confirmed that ∆Np63α has most significant effects on these three aspects of tumour biology.

5.3.1 Silencing efficiency of PRSS23 and BMP2K siRNA
Pre-designed siRNA oligonucleotides were used for gene knockdown experiments. Sequence-specific PRSS23 and BMP2K siRNA were individually obtained from Dharmacon®. These each consisted of four targeting sequences for the respective target genes, and these were used as a Custom SMARTTM pool to knockdown endogenous PRSS23 and BMP2K in MiaPaca 2 cell line. A non-targeting RISC-free® control sequence (Dharmacon Research) was also used as a non-silencing negative control.

The silencing efficiencies of PRSS23 and BMP2K SMARTpool siRNAs (Dharmacon Research) were examined by transient tranfections in MiaPaca 2 cells. This cell line was selected as it is a confirmed p63-overexpressing cell line, and was also the cell line used for microarray experiments. Cells were transfected with non-targeting RISC-free® control siRNA and PRSS23 or BMP2K siRNA, using DharmaFECT® transfection reagent 2 (section 2.3.3; Table 4.1). The efficiency of gene knockdown was determined at 48 hours (Fig. 5.5), using qRT PCR; samples and no-template controls (RNase free water) were tested in triplicate and an internal control was run alongside the samples using 18s primers (section 2.12.4). Relative expression of each target gene was determined accordingly, using the ddCT method (section 2.14.2). 

The results below (Fig. 5.5) confirmed that the PRSS23 and BMP2K SMARTpool siRNAs used, both demonstrated highly efficient mRNA knockdown of the selected target genes (98% and 90% respectively). This order of gene knockdown was confirmed from two separate experiments.

Fig 5.4: Efficiency of gene knockdown using PRSS23 and BMP2K siRNA using qRT PCR. MiaPaca 2 cells were transfected as indicated and total RNA harvested after 48 hours. qRT PCR analysis of the indicated mRNA levels was performed. Data was normalised to 18s mRNA levels. The control siRNA-transfected sample was set at 1 to generate relative mRNA expression levels for each transcript analysed. The graph represents ddCT values obtained from three PCR replicates, expressed as a percentage. 

Having confirmed the efficiency of selective target gene knockdown using PRSS23 and BMP2K SMARTpool siRNAs, the effects of these two genes on tumour biology were investigated using this RNA interference approach.
5.3.2 Effect of PRSS23 and BMP2K on cell growth






Fig. 5.5: Effect of (A) PRSS23 and (B) BMP2K expression on cell growth. MiaPaca 2 cells were transfected with PRSS23 and BMP2K siRNA. 24 hours following transient transfection, cells were seeded in 24 well plates. Cell counts of control and treated cells were measured every 24 hours, in triplicate. Each point represents the mean cell count at each timepoint. Statistical analysis was performed using the 2 way ANOVA test (* P<0.05, ** P<0.01, *** P<0.001). 

The results confirmed that both PRSS23 and BMP2K expression promotes cancer cell proliferation as compared to their respective ‘derivative’ knockdown cells, to varying degrees. However, this difference was only notable in PRSS23-expressing cells compared with PRSS23 siRNA-treated cells, and this was statistically significant from 72 hours and thereafter (Fig. 5.6(A)). The effect of BMP2K expression was suggestive of a similar effect on cell growth, but the magnitude of this effect was minimal and only found to be significant at the final timepoint, at 144 hours (Fig. 5.6(B)).  Put together, these findings support a pro-proliferative, oncogenic role for PRSS23, which depicts a very similar effect on tumour cell growth as ΔNp63α. This would suggest that PRSS23 may represent an important downstream target gene for ΔNp63α, through which its effects on tumour cell proliferation maybe mediated.


5.3.3 Effect of PRSS23 and BMP2K on cell migration









The results show that both PRSS23 and BMP2K expression promotes tumour cell migration, but this result was only statistically significant for PRSS23 (Fig. 5.7(A)). Although BMP2K-expressing cells also showed increased cell migratory potential, the difference was not statistically significant when compared with BMP2K knockdown cells (Fig. 5.7(B)). Therefore, the results above suggest that PRSS23 maybe an important downstream target gene for ΔNp63α, through which its effects on cell migration could be mediated.


5.3.4 Effect of PRSS23 and BMP2K on chemosensitivity










Table 5.3: EC50 values by MTS assay 72 hours after drug treatment. Statistical analysis using Unpaired T test was used to determine P values for the difference in sensitivity of each cell line according to PRSS23 and BMP2K expression.


Drug	Control siRNA	PRSS23 siRNA	BMP2K siRNA	













Figure 5.7: Effect of (A) PRSS23 and (B) BMP2K expression on chemosensitivity. Cell death was measured by MTS assay, 72 hours following drug treatment with 5FU or gemcitabine. Each cell line was treated in duplicates, to determine mean EC50. Representative mean EC50 ± SEM are shown from a single experiment. Statistical differences in chemosensitivity was analysed using Unpaired T test (* P<0.05, ** P<0.01, nsd=no significant difference).


































6.0 p63 expression in primary human oral squamous cell carcinomas (OSCC) and pancreatic ductal adenocarcinoma (PDAC), and elucidation of its contribution to tumour biology
6.1 Evaluation of p63 expression in primary human oral squamous cell carcinomas (OSCC) and pancreatic ductal adenocarcinoma (PDAC)
6.1.1 p63 expression in primary OSCC
Numerous studies have reported p63 overexpression in up to 80% of primary head and neck squamous cell carcinomas, and also in a number of other squamous epithelial malignancies [122]. However, a distinction regarding the precise isoforms that are upregulated is unclear; early studies of p63 expression did not discriminate between different isoforms, using generic anti-p63 antibodies for immunohistochemical analysis [185],[243]. However, more recent reports have attempted to address this using RT-PCR coupled with Western blot. Crook et al performed IHC staining using anti-p63 4A4 antibody in 12 nasopharyngeal tumour specimens, which confirmed positive p63 expression in malignant epithelial cells [172]. In order to further differentiate p63 isoform upregulation, they subsequently performed RT-PCR using ΔN and TA-specific primers, which confirmed that ΔNp63 was found to be more abundant in tumour specimens, with low or negligible levels of TAp63 [172]. It is therefore concluded that ΔNp63 is the dominant isotype in NPC, but there is no clear confirmation regarding the precise splice variant. Interestingly however, Thurfjell et al also used RT-PCR to study individual p63 isoforms in HNSCC [216]. They confirmed that mRNA expression of the ΔN and p63α isoforms predominated, however this was not evaluated at the protein level [216]. Although a number of reports have described immunohistochemical analysis for p63 protein overexpression in HNSCC [185], [243], [244], it would appear that they have either used the non-specific 4A4 antibody or a ΔNp63 antibody. Therefore, to our knowledge, there are no studies that have clearly identified isoform specificity with respect to p63 upregulation in HNSCC.
This study aimed at firstly confirming p63 overexpression in OSCC, and furthermore, elucidating the precise splice variant that is upregulated. Initial immunohistochemical analysis was performed in 12 primary oral carcinoma specimens using the 4A4 antibody to determine the prevalence and pattern of p63 expression in OSCC (Fig. 3.1). Immunoreactivity for p63 was intense in the nuclei of the basal and suprabasal layers of normal oral squamous epithelium, consistent with the literature, which confirms that p63 is expressed in normal epithelial tissues, in which it has a crucial regulatory role in its embryological development. In cases of OSCC, the pattern of p63-positive expression noted in squamous cell carcinoma suggests p63 upregulation is closely related to the undifferentiated state in basal epithelial cells, and rapidly downregulated as they become more differentiated. In advanced cases, p63 was more diffuse throughout the mass of tumour cells of invasive lesions. Put together, this pattern of p63 expression which is consistent with previous reports in the literature, may implicate a role for p63 expression early in tumourigenesis. Furthermore, it would also suggest that there is a tendency for lower p63 expression in less differentiated tumours. 

However, the results so far do not address p63 isoform-specific detection. The specificity of 4A4 antibody in differentiating between p63 isoforms was therefore evaluated. Most p63 isoforms were overexpressed through transient transfection of a cell line (MCF 7), that does not endogenously express p63. Transfected cell lysates were probed using the 4A4 antibody for Western blot, and this confirmed that the 4A4 is a pan-p63 antibody which does not differentiate between the two families of isoforms (TAp63 and ΔNp63) nor indeed between any splice variants (Fig. 3.3). As ΔNp63α is widely reported to be the isoform that is implicated in tumourigenesis of several cancers, further analysis was performed to determine if this isoform is indeed the predominant p63 isoform implicated in OSCC. Two further antibodies, anti- ΔNp63 and anti-p63α were evaluated using the MCF 7 clones transfected with most p63 isoforms. Western blot analysis confirmed that these two antibodies did in fact show specificity for ΔN and α-isoforms respectively (Fig. 3.4). Further IHC staining was performed in a further 10 primary OSCC specimens, using these two antibodies in parallel (Fig. 3.5). The results produced symmetrical, mirror images of p63 staining in a spectrum of neoplasms ranging from early dysplasia to advanced poorly differentiated carcinomas. These results provide clear, comprehensive confirmation that it is indeed the ΔNp63α splice variant that is upregulated in primary OSCC.  

The clinical relevance of p63 upregulation in HNSCC has previously been investigated by correlation with a number of clinicopathological parameters. Weber et al found no statistical significant correlation of p63 expression status to tumour stage or grade [185]. Similarly, Dong et al also did not identify any significant correlation between p63 expression and TNM staging, lymph node metastasis or overall survival in their series of primary laryngeal carcinomas [245]. However, interestingly, Lo Muzio et al did report a significant correlation between the degree of p63 expression and a poorer prognosis in patients with OSCC, but no significant correlation with pathological features including tumour size, recurrence and metastases [218]. In the present study, correlation between p63 expression and pathological features was not evaluated; p63 overexpression is clearly recognised in normal squamous epithelium, and therefore, its potential as a prognostic biomarker would be of limited clinical value, in real practical terms. Therefore, ΔNp63α overexpression in OSCC was not assessed further, with respect to its correlation with any clinicopathological features.

6.1.2 p63 expression in primary PDAC
p63 expression in pancreatic cancers has recently been the subject of active investigation, although the data available so far are limited. It is reported that p63 is not expressed in normal pancreas and is also absent in pancreatic intraepithelial neoplasia (PanIN) of various grades [184]. With regards to invasive carcinomas, the reported prevalence of p63 overexpression in these tumours is hugely variable, ranging from 4% to 68.2% of ductal adenocarcinomas of the pancreas [184], [220], [183]. 

Most reports in the literature refer to p63 upregulation in pancreatic cancers, with no reference to isoform-specific overexpression [220], [183], [246]. The only series to address this was performed by Basturk et al [184]. They tested immunohistochemical expression of ΔNp63 in 50 cases of pancreatic adenocarcinoma using a commercially available p63 antibody, available from Santa Cruz Biotechnology. They concluded that this detected ΔNp63 expression in pancreatic neoplasms, but only in areas of squamous differentiation. However, there were no data provided regarding the sensitivity of the antibody used with respect to different p63 isoform detection, and furthermore, there was no mention of the precise splice variant that is predominant in this tumour model.  Put together, the data for p63 expression in pancreatic cancer are very limited and sparse. The significant variation in prevalence of p63 overexpression and lack of detail regarding isoform-specific upregulation demands further clarification. 

This part of the study sought to investigate the pattern and prevalence of p63 overexpression in a large series of 63 cases of primary PDAC, and furthermore, elucidate which splice variant is predominantly expressed. Furthermore, the prognostic value of p63 protein expression in PDAC was evaluated.

A total of 63 primary PDAC specimens were analysed for p63 expression, using 4A4 antibody for immunohistochemical analysis (Fig. 3.2). This confirmed that p63 is not expressed in normal pancreatic ductal epithelium, in keeping with the reported literature [184]. It was however detected in a spectrum of neoplasms, ranging from early to late disease. Further IHC testing was performed using anti-ΔNp63 and anti-p63α antibodies (Fig. 3.5), which showed that ΔNp63α is the predominant isoform expressed in pancreatic cancers. 

As normal pancreatic tissue does not express p63, the clinical implications of ΔNp63α expression in pancreatic cancers would be of potential clinical value, and was therefore further evaluated. Interestingly, there is a total void in the literature with respect to data regarding its clinical significance; there are no published reports that have evaluated p63 expression in pancreatic cancers against any clinicopathological features. Therefore, the expression of ΔNp63α in all 63 primary pancreatic ductal adenocarcinoma specimens was further analysed and moreover, its potential for use as a biomarker to predict prognosis was reviewed.

p63 expression was identified in 35% (22/63) of cases. In 9.52% (6/63) of pancreatic cancers there was a higher level of ∆Np63 expression (>10% of cancer cells were p63-positive) and the higher level of ∆Np63 expression was significantly correlated with a shorter survival (Table.3.2); the median survival time for the patients with a higher level of ∆Np63 expression was only 0.75 months as compared with 12.0 months for p63-negative and low p63-positive patients (Fig. 3.7). This difference was highly significant (P<0.0001), with an average survival advantage of nearly one year in patients with absent or low levels of p63 immunoreactivity in their primary tumours. These data are the first to report any clinical significance of p63 expression in pancreatic cancer, and suggest its strong, potential value as a prognostic biomarker for primary PDAC.

Further analysis of the relationship of p63 staining with other clinicopathogical features was conducted, including sex, age, tumour stage, nodal status and metastasis (Table 3.3). Although data analysis demonstrated an association between the percentage of p63-positive cells and tumour stage, this was not statistically significant. There was no significant correlation between any of the other clinicopathological features and p63 immunoreactivity. 


6.2 Effect of p63 expression on tumour biology
ΔNp63α is recognised to be the predominant isoform that is expressed in normal basal epithelial cells as well as some cancers. In normal epithelial tissues, it promotes cellular proliferation through regulation of shared p53 target genes in addition to p53-independent target elements [122], [135], [132]. However, its precise contribution in tumourigenesis is ill defined. Improved understanding of the distinctive properties of ΔNp63α will help to clarify its influence on tumour biology. This would potentially be beneficial in enabling more specific ways to target this protein for future cancer therapy strategies.

Having previously comprehensively confirmed that ΔNp63α is the individual p63 isoform that is upregulated in primary OSCC and PDAC, the next part of this study sought to evaluate its functional effects on characteristics that are pertinent to carcinogenesis. Initially, a panel of human head and neck and pancreatic cancer cell lines was screened for p63 overexpression, and ∆Np63 expression was clearly detectable in all five head and neck cancer cell lines tested, and two of the eight pancreatic cancer cell lines screened, namely MiaPaca-2 and Suit-2 (Fig. 4.1 and Fig. 4.2). 

Having confirmed ΔNp63α-specific upregulation in the human head and neck and pancreatic cancer cell lines, its functional effects were evaluated. All functional studies were performed using an RNA interference approach, whereby Custom SMARTTM pool TP63 siRNA was used to knockdown endogenous ΔNp63α, in order to study the effects of this gene. After confirming efficient and persistent p63 knockdown (Fig. 4.5), a number of in vitro functional assays were performed.

The results demonstrated that all cell lines expressing endogenous ΔNp63α formed significantly larger and greater numbers of colonies, as compared with their p63 knockdown derivatives, in soft agar colony formation assays. Reciprocally, two pancreatic cancer cell lines transiently transfected with pcΔNp63α confirmed the same pattern. These results, together with the earlier immunohistochemistry analysis, strongly support a tumourigenic role for ΔNp63α, and moreover are indicative of a contributory role in tumour initiation.    

To support these data further, the effect of ΔNp63α expression on tumour cell proliferation was studied using cell growth assays, in cell lines from both tumour models (Fig. 4.8). The results obtained were consistent, in that they demonstrated that all cell lines overexpressing endogenous ΔNp63α had an increased potential for tumour cell growth, as compared with their p63-knock down counterparts. This functional role of ΔNp63 has previously been reported in HNSCC [247], [212], and furthermore, it has at least in part been attributed to its ability to repress apoptosis mediated by TAp73 [248]. Interestingly, there are no studies in the literature to date with respect to this proliferative function of ΔNp63α in pancreatic cancer. The results presented in this study provide strong evidence for a pro-proliferative and oncogenic effect of ΔNp63α in both head and neck and pancreatic tumours. 

Next, the effect of ΔNp63α expression on tumour cell migration was evaluated using transwell migration assays. The results showed a very interesting finding that was notably tumour-specific. Endogenous expression of ΔNp63α in pancreatic cancer cell lines demonstrated a significant positive effect on cell migration. This was true for all pancreatic cancer cell lines tested, and this effect was confirmed with both p63 knockdown experiments in MiaPaca 2 and Suit-2 cells as well as the reciprocal overexpression experiments with pcΔNp63α plasmid for transient transfection in PT 45 cells. This would suggest that pancreatic tumours expressing ΔNp63α should have a more aggressive phenotype, with greater migratory potential. These data do in fact support the previous clinical correlates of ΔNp63α expression described earlier, in our cohort of patients expressing p63. Those results confirmed that patients expressing high levels of ΔNp63α had more aggressive tumours, with a poorer overall survival. 

Conversely however, the results from the in vitro migration assays in head and neck cancer cell lines were entirely contradictory. These results showed that the control cells overexpressing endogenous ΔNp63α had a reduced potential for tumour cell migration, as compared with p63 knockdown cells.  This pattern of results was consistent in all three cell lines tested and statistically significant in two of the three. Put together, this would suggest that ΔNp63α has an inhibitory effect on cell migration, in the head and neck model, which is not inconsistent with the suggestion that ΔNp63α expression contributes to the early stages of tumourigeneis in HNSCC [122].

Trink et al used transcriptional profiling to study the transcriptional role of p63 isoforms and confirmed that the ΔNp63α isoform regulates a specific set of downstream target genes, through the short transactivation domain that it retains [132]. Some of these genes reported were a unique set of p53-independent transcriptional targets, which might suggest that this isoform may have alternative roles, separate to p53-related responses to cellular stress. Carroll et al (2007) also performed transcriptional profiling and identified several families of genes implicated in cellular adhesion that are regulated by ΔNp63α, including extracellular matrix (ECM) components, integrins and components of adherens/desmosomal junctions and adhesion complexes [249].  Its regulation of these key matrix adhesion proteins is likely to be important in maintaining cellular attachment to the underlying basement membrane, which is crucial for epithelial tissue integrity. Although these studies were done in normal epithelial cells, to elucidate the function of ΔNp63α in the proliferative basal layers of a range of normal stratified epithelia (eg. skin, breast and prostate), the expression pattern of ΔNp63α in head and neck squamous carcinoma cells closely resembles these. It could therefore be postulated that ΔNp63α expression in head and neck cancer cells is similarly central to maintaining epithelial cell adhesion, and therefore loss of p63 expression might result in physical detachment of tumour cells from the ECM, enabling enhanced migratory potential. However, co-expression of cellular adhesion proteins in ΔNp63α-overexpressing cells, and the effect of p63 knockdown on such cellular molecules were not screened for in this study. 

My experiments showed no significant differences in the invasive potential in any of the cell lines tested, from both pancreatic and head and neck cancer origin, when comparing ΔNp63α-expressing cells with their p63-knockdown derivatives. To validate this further, the effect of ΔNp63α on tumour cell invasion was studied using in vitro organotypic cultures. These three dimensional culture models provide a closer representation of tumours in vivo, particularly with respect to the interactions between tumour cells and stromal fibroblasts. These were therefore done in two pancreatic and two head and neck cancer cell lines, to compare invasion between control and p63-knockdown cells. The results did not demonstrate any noticeable difference between the treated cells, in the degree of tumour cell invasion into the type I collagen and fibroblast matrix layer. Therefore, there was no clear effect of ΔNp63α on the invasive potential of cells observed, which mirrored the results obtained from transwell invasion assays. Although there are no reports in the literature that define a functional effect of ΔNp63α expression on invasiveness in pancreatic cancer, there are some emerging data to suggest that this isoform is implicated in suppressing the invasive potential of human squamous cell carcinomas [204], [206], [207]. Higashikawa et al recently showed that inhibitor of differentiation-3 (Id-3), a transcriptional target of ΔNp63α, suppresses the invasive potential of human oral SCC cells [206]. This was shown to be mediated through downregulation of extracellular matrix associated proteolysis, in particular the epithelial-mesenchymal transition (EMT)-associated MMP-2 [206]. Similarly, Kommagani et al have identified vitamin D receptor (VDR) to be a separate transcriptional target for ΔNp63α, through which it also mediates an inhibitory role on tumour cell migration and invasion [207]. These recent reports would suggest that ΔNp63α may have an inhibitory effect on tumour invasiveness. However, the results presented in this thesis did not confirm any effect on this distinct functional role, or any obvious trend in patterns of cellular behaviour, in either of the tumour models studied. This may reflect a cell line-dependant phenomenon, which was mitigated against in the cell lines used in this study because of their genetic background, or alternatively may suggest that this functional role is less important and not ubiquitous in all tumours.

Finally the effect of ΔNp63α on chemosensitivity to conventional chemotherapeutic agents was tested. The chemosensitivity of a panel of pancreatic and head and neck parental cell lines was tested when treated with 5-FU and gemcitabine, and 5-FU and cisplatin respectively, using MTS cytotoxicity assays. The results obtained demonstrated an interesting pattern which was again tumour type-specific. In the pancreatic cancer cell lines tested, endogenous ΔNp63α expression clearly induced a significant degree of chemoresistance to both 5-FU and gemcitabine. Following p63 knockdown, there was an increased sensitivity to chemotherapy. This difference in its effect on cytotoxicity was statistically significant for both pancreatic cancer cell lines tested, and for both drug treatments, but greatest for Mia Paca 2 cells treated with gemcitabine. This important effect of endogenous ΔNp63α expression on the response to chemotherapy of pancreatic tumours has not previously been reported on in the literature, but is clearly of potential clinical relevance. The results obtained in this study would imply that ΔNp63α expression may provide an important potential cancer therapeutic target, which should be considered in the future, in an attempt to improve patients’ response to these treatments. 

Conversely, the results for chemosensitivity in the head and neck cell line, Fadu, were quite different. There was no significant effect of ΔNp63α expression on sensitivity to 5-FU. There was however, a noticeable difference in the cytotoxic effect on cells when treated with cisplatin. Endogenous ΔNp63α expression was found significantly to enhance tumour cell killing on exposure to cisplatin therapy, with a lower EC50 value, as compared with its p63-knockdown counterpart. This would suggest that head and neck tumours expressing high levels of ΔNp63α might exhibit a favourable response to platinum-based treatment. These results do in fact support previously published data in a subset of both breast and head and neck tumours, which have also demonstrated enhanced chemosensitivity to cisplatin in ΔNp63α-expressing tumours [210], [189],. This effect has been proposed to be due to the inhibitory interactions of ΔNp63 and TAp73; upon cisplatin treatment, TAp73 undergoes c-Abl-dependent phosphorylation, which promotes dissociation of the TAp73/ΔNp63α protein complex, which in turn enables TAp73-dependent transcription and apoptosis [210], [189]. Such cellular interactions of the p53 family genes has not been evaluated in this study, but nonetheless, the results from both the pancreatic and head and neck cell lines would suggest that ΔNp63α expression may have a potential role in stratifying patients for treatment with particular cancer therapeutics. At the very least, it would be worth considering the value of screening ΔNp63α expression in patients with these tumours, to predict their likely response to chemotherapy treatments, to facilitate better treatment planning. 

6.3 Evaluation of p63 transcriptional targets in pancreatic cancer
The earlier work in this thesis has comprehensively confirmed overexpression of ΔNp63α in human HNSCC and PDAC, with significant prognostic implications for patients with pancreatic cancer. It has also clearly demonstrated some important functions of ΔNp63α on tumour biology. These included significant effects on tumour cell growth and proliferation, cell migration and also chemosensitivity. Therefore, in an effort to further our understanding of this tumourigenic process, and to begin to define the molecular pathways that are activated by ΔNp63α, microarrays were utilised to create a p63-dependant transcription profile. Affymetrix GeneChip high-density oligonucleotide microarrays were used to identify ΔNp63α-dependent changes in gene expression in a human pancreatic cancer cell line (MiaPaca 2).

A gene profile list of transcriptional targets for ΔNp63α was generated, which included a total of 237 gene expression changes (P<0.05). The validity of these results was supported by the confirmation of very high differential expression of the probe set specific to TP63, as would be expected following p63 knockdown. 

To validate the microarray data, qRT PCR was performed to follow the relative expression levels of seven selected transcriptional targets. This confirmed the expected changes in mRNA expression of the chosen target genes, both in terms of the expected orders of magnitude, and also the expected direction of fold-changes (positive or negative), as suggested by the microarray data. Overall, these results supported the validity of the microarray data, at gene transcription level, to enable further work to be conducted. 

Of the seven validated target genes, two particular ΔNp63α transcriptional targets were selected for further evaluation. Although both these genes are not yet characterised in the literature, they were chosen largely based on their potential relevance to carcinogenesis. These two genes included protease, serine, 23 (PRSS23) and BMP2-inducible kinase (BMP2K). These represent genes from the families of proteases and kinases respectively, which are responsible for two fundamental regulatory mechanisms, namely proteolysis and phosphorylation, both of which are central in orchestrating cellular functions in cancer. 

Although differential expression of PRSS23 and BMP2K mRNA were confirmed following ΔNp63α knockdown, neither of these gene expression changes were confirmed at the protein level, as at the time of conducting the study, there were no commercial anti-PRSS23 antibodies available. Differential expression changes in BMP2K protein levels were tested for using a commercial anti-BMP2K antibody but unfortunately this did not demonstrate any identifiable differences in BMP2K expression as a result of ΔNp63α knockdown. This could be either due to changes in BMP2K transcription that were not translated to differential changes at the protein level. Alternatively, it could be that ΔNp63α knockdown does result in differential expression changes in both transcription and translation of BMP2K, but this was not detected with the anti-BMP2K antibody used. This may require further experimental optimisation, or alternative antibodies for this protein should be tested.

Nevertheless, the significant changes in mRNA levels of both these genes (PRSS23 and BMP2K) could still be of some significance in activation of cellular pathways that regulate some of the biological functions of ΔNp63α, as this is well recognised to function fundamentally as a transcription factor. The cellular effects of these two transcriptional targets were therefore further evaluated, in order to determine if either of these genes have a role in mediating the effects of ΔNp63α on tumour cell biology. 

Sequence-specific PRSS23 and BMP2K siRNA were individually used to knockdown endogenous PRSS23 and BMP2K respectively in MiaPaca 2 cells. Non-targeting RISC-free® control sequence was used in parallel, as a non silencing negative control. qRT PCR demonstrated highly efficient gene knockdown of each of these target genes, as compared with control cells. 

A number of subsequent in vitro functional studies were conducted in MiaPaca 2 cells, to evaluate the effects of each of these two target genes in turn, on tumour cell proliferation, migration and chemosensitivity. These particular functional effects were chosen for analysis, as ΔNp63α knockdown had the most pronounced effects on these three aspects of tumour biology (Section 4.0). They were therefore further evaluated to determine if either PRSS23 or BMP2K were potential important downstream transcriptional targets for ΔNp63α, through which it could mediate these effects.

Results from the functional studies confirmed that both PRSS23 and BMP2K expression had similar effects to ΔNp63α on all these aspects of tumour biology. That is to say, that endogenous expression of each of these target genes promoted increased tumour cell proliferation, an increased migratory potential and resistance to tumour cell killing when treated with 5-FU. Overall, MiaPaca 2 cells expressing endogenous PRSS23 or BMP2K produced the same functional phenotype as ΔNp63α-expressing cells, when compared with their respective knockdown derivatives. These results were very encouraging, as they were suggestive of these genes being potentially important downstream target genes for ΔNp63α. Of these two transcriptional targets, PRSS23 expression resulted in far more pronounced and statistically more significant effects with respect to these functional effects. 

PRSS23 is a member of the trypsin class of serine proteases. These are a family of protease enzymes, whose activity is characterised by a catalytic serine amino acid residue in the active site of the enzyme. PRSS23 was only recently cloned (in 2006), and was found to be highly homologous to PRSS35 [250]. It was also found that this gene appears to be highly conserved in vertebrates (75 – 99% homology), and may be an important ovarian protease [250], [251]. However, the role of PRSS23 in cancer has not so far been evaluated, but theoretically could be of biological relevance.

Proteases are critical for a number of essential biological processes. These include proteolytic degradation of extracellular matrix (ECM) components, modulating growth factor or cytokine actions by regulating their bioavailability and controlling levels of cell surface proteins. Therefore, proteases are potentially critical determinants of cellular proliferation, differentiation, migration and adhesion [252], [253], and as such should be vital for maintaining cellular homeostasis or in upsetting the balance towards a tumourigenic process. It is therefore conceivable that the functional effects of PRSS23 expression observed in this study in promoting tumour cell growth and increasing tumour cell migration are as a direct result of the proteolytic effect of PRSS23. The precise proteolytic activities involved have not yet been characterised, but it is possible that it facilitates tumour cell proliferation by acting on local paracrine factors to promote growth. It could also have a role in remodelling the ECM or have an effect on adhesion molecules, which could in turn have a pro-migratory effect. Its effect on chemosensitivity may also be related to degradation of the ECM, which may promote tumour cell killing when treated with 5-FU, through deficient cell – matrix adhesion.

As the physiological substrates for this protease are unknown, one can only speculate about the possible role PRSS23 may play in this process. However, overall it is fitting to identify a protein with proteolytic activity which could feasibly have significant tumourigenic effects, and the results from this study so far, would suggest that it is potentially an important downstream mediator of ΔNp63α. The mechanisms through which p63 potentially upregulates PRSS23 remains undefined. It is likely that as a transcription factor, ΔNp63α may function by binding to the promoter region of PRSS23, or alternatively interact with separate p63-responsive binding elements. It would be valuable to further characterise the interaction between these two genes, through careful gene sequence analysis.  

Another important family of proteins that are widely implicated in tumourigenesis are protein kinases. These are pivital regulators of cell signalling that modulate their effects via site-specific phosphorylation events. These key regulatory modifications impact on cellular metabolism, growth and proliferation, and are commonly involved in tumour formation. Therefore, the second transcriptional target for ΔNp63α evaluated was BMP2K. This gene is the human homolog of mouse BMP2-inducible kinase. The gene product is a putative serine/threonine protein kinase, which is thought to have a role in osteoblast differentiation and skeletal development. Serine/threonine kinases phosphorylate serine or threonine residues in their substrates, and their expression is altered in many types of cancers. BMP2K was recently identified as a novel protein kinase that is involved in site-specific phosphorylation, related to increased mitosis [254].  However, the functional effect of BMP2K has not specifically yet been studied in cancer, and for this reason, it was selected for further analysis. The results demonstrated increased tumour cell proliferation in cells expressing endogenous BMP2K, as compared with knockdown cells, which would support the findings of the phosphoproteome studies done by Daub et al [254]. However this pro-proliferative result was only statistically significant at a single timepoint (144 hours), and is therefore of doubtful clinical significance. BMP2K-expressing cells also demonstrated a trend towards increased tumour cell migration, but this result was not significant. Finally, the effect on chemosensitivity did show an increased cytotoxic effect of BMP2K silencing in cells treated with 5-FU. This finding may also be the result of disabled cell cycle regulation, resulting from low cellular abundance of the protein kinase which is no longer available for phosphorylation. Although the results in this study support a role for BMP2K in promoting tumour cell proliferation, migration, and affecting chemosensitivity to 5-FU treatment, the magnitude of these effects is far less significant as compared with PRSS23, and it is therefore likely to represent a less important cancer-related target for ΔNp63α.



























CONCLUSION AND FUTURE WORK

Despite substantial efforts, the incidence and mortality rate of both HNSCC and PDAC have remained largely unchanged over the last three decades. In order to improve the outcome of cancer patients, the focus of future cancer studies needs to identify potential therapeutic target genes that both significantly affect the behaviour of tumour cells and also the outcome of this disease. 

This study has focussed on the clinical and biological implications of p63 in these two tumour models. It has confirmed that ΔNp63α is the predominant isoform that is upregulated in these cancers. It has explored the functional effects of ΔNp63α on tumour initiation, progression and prognosis. 

One of the key findings from this study was the strong evidence to show a role for ΔNp63α both in tumour initiation, based on immunohistochemical analysis and in vitro soft agar assays, and also its contribution in affecting prognosis of PDAC patients. Since ΔNp63α expression in the primary tumours had such a profound effect on the survival of pancreatic cancer patients, it was important to assess further the functional significance of ΔNp63α on cell migration and invasion. 

Overall, functional analysis has confirmed an oncogenic role for ΔNp63α, which affected tumour cells’ behaviour; the results have demonstrated opposing effects on tumour cell migration, which are clearly tumour-specific. In the head and neck model, overexpression of ΔNp63α was associated with less aggressive tumours, with reduced migratory potential. In pancreatic cancers however, loss of ΔNp63α may be indicative of tumours that have acquired additional mesenchymal properties which may correlate with refractory clinical behaviour.
Furthermore, the data have shown that analysis of ΔNp63α expression may have a potential place in predicting response to chemotherapeutic agents. It may also offer potential as an interesting target for anti-cancer therapies.

Finally, gene expression profiling has been used to develop a ΔNp63α transcriptional signature. Some target genes identified were functionally validated, and of these PRSS23 was identified as a novel p63 target which may be implicated in mediating the tumourigenic effects of ΔNp63α. 
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